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Introduction: Warfarin is the most commonly prescribed drug for stroke prevention among 
Atrial Fibrillation (AF) patients, especially in older adult populations, but medication 
nonadherence reduces its effectiveness in clinical practice. Group Based Trajectory Models 
(GBTM) have been used to identify distinct patterns of adherence behavior related to various 
medications and understand the patient characteristics associated with each trajectory. The 
objectives of the study were: 1) Describe trajectories of warfarin adherence among Medicare AF 
patients, 2) Assess impact of adherence trajectories on AF-related hospitalization, 3) Estimate the 
AF-related direct costs for each adherence trajectory group.
		
 
Methods: We identified elderly AF patients initiating warfarin treatment during 2008-2010 
using data from a random sample of Medicare beneficiaries. The study’s first aim is to classify 
patients into different trajectory groups based on their monthly adherence patterns using a 
Group-Based Trajectory Model (GBTM). A multinomial regression model was used to assess 
associations between baseline characteristics and adherence trajectories. The second aim is to 
evaluate the association between adherence trajectories and time to first hospitalization related to 
stroke or bleeding event. Hospitalization events due to bleeding or stroke were identified using 
corresponding ICD-9 codes, and a Cox proportional hazard model was performed.  The third aim 
of the study is to calculate AF-related direct medical costs associated with each trajectory group. 
SASv9.4 was used for analysis. 
Results: Among 3,246 beneficiaries who met inclusion criteria, six adherence trajectories were 
identified: 1) rapid-decline non-adherence group (11.5%), 2) moderate non-adherence group 
(24%), 3) rapid-decline then increasing adherence group (6.8%), 4) moderate-decline non-
adherence group (8.2%), 5) slow-decline non-adherence group (24.3%), and 6) perfect adherence 
group (25.3%). Even though no statistical significances were found in the hazard of 
hospitalization among the adherence groups, there were higher odds of hospitalization among the 
lower adherence groups compared to perfect adherence group. Outpatient and monitoring costs 
were significantly higher in the lower adherence trajectories compared to perfect adherence 
group. 
Conclusion: The GBTM is considered an innovative methodological approach that can be 
applied to longitudinal medication adherence data and account for the dynamic nature of 
adherence behavior in a better way than traditional adherence measures.
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Chapter 1: Introduction 
1.1 Introduction 
Medication non-adherence is a major obstacle to improving healthcare outcomes. Poor 
medication adherence is associated with numerous adverse health outcomes.1 Older adults, 
patients with critical conditions, and those treated with medications with narrow therapeutic 
windows are at increased risk for non-adherence related adverse events.2  
Atrial Fibrillation: 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical 
practice.3 The condition affects more than 3 million Americans, and this figure is projected to 
increase to 8 million by 2050.4 Approximately 70% of AF patients are between the age of 65 and 
85 years.5  AF is a major risk factor for ischemic stroke (IS). Patients with AF are five times 
more likely to develop IS than those without AF.3 Risk of IS increases in AF patients with 
advancing age and the presence of other cardiovascular diseases, including hypertension, heart 
failure, diabetes mellitus, and history of previous stroke or transient ischemic attack (TIA).4  
Stroke contributes to substantial morbidity and mortality among the AF population. AF 
patients who experience a stroke have increased mortality rates relative to those who do not.6 
Moreover, strokes may cause an array of disabilities, such as vision impairment, inability to walk 
without assistance, cognitive deficits, and depression. Stroke complications are associated with a 
notable socioeconomic burden on both individuals and the healthcare system. In the 
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United States, the mean lifetime cost per patient with an IS has been estimated at $140,048.6 
Inpatient care is considered to be the main driver of stroke-related costs, accounting for 70% of 
costs in the first year after a stroke.6 After the first year of survival, costs of lost productivity and 
rehabilitation can be significant. According to the U.S. Centers for Disease Control and 
Prevention (CDC), the stroke costs United States 34.6 billion dollars annually.7 
Warfarin: 
Warfarin, a vitamin K antagonist, has long been the most common treatment for 
preventing stroke in AF patients. Several clinical trials have shown warfarin to be effective in 
decreasing stroke by up to 64% compared to placebo, and it has been associated with reductions 
in mortality among AF patients.8 Effective treatment with warfarin requires patients to be 
maintained within a narrow International Normalized Ratio (INR) range between 2 to 3. 
Maintenance of that range requires regular INR monitoring and potential dosing changes due to 
the pharmacokinetic properties of warfarin.9 Specifically, a variety of drug-drug and drug-food 
interactions can significantly impact the pharmacokinetics of warfarin and patients’ INR values. 
In 1996, Rosendaal reported that extensive anticoagulation monitoring in specialized clinics 
improves treatment effectiveness and reduces complications associated with warfarin therapy.10  
Direct oral anticoagulants (DOAC): 
In recent years, direct oral anticoagulants (DOACs) have been introduced into the US 
market with the potential to overcome limitations of warfarin treatment. Dabigatran was the first 
direct oral anticoagulation agent approved by the FDA in 2010, followed by rivaroxaban in 2011, 
apixaban in 2013, and edoxaban in 2015. The DOACs, which are administered with a fixed dose 
either once or twice daily, do not require the regular monitoring needed during warfarin 
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treatment. In several clinical trials, these agents have demonstrated similar or superior efficacy 
and safety compared to warfarin for the treatment of stroke prevention in AF patients.9-12 
Use of Warfarin vs. DOAC: 
Despite the favorable data on DOAC safety and efficacy, a number of barriers have 
limited widespread utilization of the DOACs. While warfarin has a long history of clinical use, 
little evidence currently exists surrounding the long-term safety and effectiveness of the DOACs. 
Moreover, the four major clinical trials that assessed safety and efficacy of the DOACs 
compared to warfarin took place under controlled conditions, and vulnerable populations like 
elderly (aged ≥75 years) patients and those with severe renal or hepatic impairment were 
underrepresented. Thus, these trials cannot  determine conclusively that the overall safety and 
efficacy of DOACs is the same in these higher risk populations as in their lower risk 
counterparts.13 Given the lack of real world evidence on effectiveness and safety, some clinicians 
still hesitate to prescribe DOACs in higher risk patient popluations.14 Additionally, unlike 
warfarin, there is no antidote to reverse the anticoagulant effect of these agents in case of life 
threating bleeding,. Although a new antidote agent for DOACs has been approved recently, still 
there is a doubt about its effectiveness in reversing major bleeding events associated with 
DOACs. Furthermore, the acquisition costs of the DOACs, which are still under patent 
protection, are considerably higher than the cost of generically-available warfarin. Although 
multiple studies have found that the DOACs can be cost-effective compared to warfarin in AF 
patients, many of these studies reported that their results apply only when INR control with 
warfarin treatment was poor.9,15 In other words, warfarin might be more economical in patients 
with excellent INR control, as is commonly the case in patients treated at anticoagulant 
clinics.10,12 
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For these reasons, the majority of AF patients in the US are still treated with warfarin.13 
According to a recent study by Desai et al., warfarin is the most commonly prescribed drug for 
AF patients with CHADS2 scores ≥ 2.16 It is likely that warfarin will remain the most commonly 
used anticoagulant in AF patients, especially among older adults, and switching to DOACs may 
not be necessary for patients who are well maintained on warfarin.13  
Medication Non-adherence: 
Poor adherence to warfarin therapy is associated with increased risks of hospitalization 
and mortality.2 These risks are especially high among the elderly population due to age-related 
declines in mental and physical health.16 In the US, almost one-third of annual emergency 
hospitalizations for adverse drug events have been attributed to warfarin, a finding that is even 
more pronounced in older adult patients.17 These adverse drug events may be related to the 
difficulty of warfarin dosing, the need for regular monitoring, and the many drug-drug and drug-
food interactions that impact the drug’s pharmacodynamics. Proper adherence is essential to 
maintaining a therapeutic INR, as even one missed dose can significantly impact the INR. 
      Despite the documented importance of warfarin adherence, nonadherence to the 
medication is widespread.  Kimmel et al. used the medication event monitoring system (MEMS) 
to assess adherence to warfarin treatment and reported that up to 40% of patients were poorly 
adherent.18 Another study by Davis et al., using the Morisky Medication Adherence Scale 
(MMAS), found that adequate adherence was only reported in 50% of the participants, and it was 
significantly associated with anticoagulation control.19 Based on the literature, patients with high 
adherence to warfarin (PDC>80%) are associated with reduction in costs and resources 
utilization compared to low adherent patients. It is estimated that well adherent patients are 28% 
less likely to be hospitalized compared to poorly adherent patients.20  
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The findings from the literature suggest that increased adherence to warfarin treatment in 
the management of AF results in improved health outcomes.21 Despite these findings and an 
array of interventions to improve warfarin adherence among AF patients, nonadherence 
continues to be a significant problem in this population. Most of the existing interventions that 
target poor adherence to warfarin are based on crude measures of medication adherence that 
consider patients to have the same adherence patterns over time. Most adherence measures rely 
on defined cut point, leading them to collapse a broad spectrum of adherence behavior patterns 
into two groups, either adherent or non-adherent. Such a dichotomization can mask important 
differences among patients’ adherence behavior, in turn having a great impact on the 
effectiveness of the intervention. For example, the optimal intervention for a patient that is 
highly adherent for short time and then discontinues the drug may differ from that of a patient 
who is consistently non-adherent throughout their treatment period. In order to better tailor 
interventions to improve warfarin adherence, there is a need for methods that can distinguish 
between different patterns of warfarin adherence, as medication adherence is a dynamic behavior 
that can change over time. In other words, there is a need for methods that not only measure 
medication adherence but are also able to accurately predict the degree and timing of a given 
patient’s non-adherence. Moreover, the ability to classify patients into groups according to their 
adherence behavior over time may allow clinicians to develop targeted adherence interventions 
for different groups.  
According to the World Health Organization (WHO), medication adherence is defined as, 
“the extent to which a person’s behavior – taking medications, following a diet, and/or executing 
lifestyle changes - corresponds with agreed recommendations from a health care provider.”1 In 
administrative claims data, medication adherence is most commonly measured using the 
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proportion of days covered (PDC) or medication possession ratio (MPR).21-23 Both measures are 
well-established and validated. However, in practice, these measures are frequently used to 
dichotomously classify patients as adherent or not relative to predetermined threshold (e.g., PDC 
> 80%). The use of the conventional adherence measures (e.g., PDC) can mask underlying 
differences in medication refill behavior.  For example, a patient with a PDC of 0.6 may have (1) 
been highly adherent during the early follow-up but become increasingly less adherent as time 
went on, (2) been poorly adherent during the early follow-up but become increasingly more 
adherent over time, or (3) been intermittently adherent throughout follow-up period. All three 
patients are considered non-adherent, but each may require a different type of intervention at 
different times to improve their adherence behavior. Studies using these measures generally 
assume that patients with similar scores maintained similar adherence patterns over the study 
period and subsequently analyze those patients as a homogenous behavioral group. However, 
underlying differences in the refill patterns and patients’ adherence behavior may play a crucial 
role in the effectiveness of their medications and subsequently health outcomes and healthcare 
utilization and associated costs. 
Group Based Trajectory Model (GBTM): 
Group-based trajectory models (GBTMs) are a new methodological approach that can 
help to summarize long-term medication adherence by taking into account the dynamics of 
medication adherence and changes in adherence behavior over time.21  GBTM is a latent class 
analysis that provides an alternative method to capture adherence behavior over time.21 Unlike 
PDC and other conventional adherence measures, GBTM is able to distinguish between different 
patterns of medication non-adherence. The model provides a framework through which to 
identify groups of individuals, termed trajectory groups, with similar behavioral patterns over a 
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period of time.24,25 The GBTM is considered a person-centered approach, like  cluster analysis, 
that take into account the relationship among individuals.26 In GBTM, patients are grouped into 
different trajectories based on their prescription refill patterns over time and summarized with an 
average adherence in an easily interpretable graphical depiction. This approach allows patients to 
be classified into different groups according to their adherence behavior over time, and the 
characteristics of patients in each group can be identified and compared. By identifying key 
characteristics associated with poor adherence trajectories, this can facilitate designing targeted 
interventions more accurately.27 Moreover, GBTMs enable measurement of both the intensity 
and the timing of medication adherence, thus capturing the dynamic nature of non-adherence 
behavior in a way that conventional measures of adherence do not. 
The GBTM has been widely used in sociological and medical research for understanding 
disease progression and behavioral development patterns in children and adolescents.24,25 In 
recent years, GBTMs have been applied to the study of medication adherence patterns and the 
associations between adherence and health outcomes.21-23 Specifically, Franklin et al. used the 
trajectory model to examine statin adherence, and Lo-Ciganic et al.22,23 applied GBTM to 
classify diabetic medication adherence patterns and their association with clinical outcomes. In 
both studies, the GBTM showed better predicative performance for clinical outcomes associated 
with each trajectory group compared to conventional methods (e.g., PDC). Moreover, this 
method has been shown to capture long-term medication adherence more accurately than 
conventional measures.21  
 The application of GBTMs to the classification of medication adherence patterns offers 
the potential to more comprehensively understand dynamic of adherence behavior and its 
associated consequences. Furthermore, the use of GBTMs in clinical practice provides a method 
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by which healthcare providers and payers can identify groups of patients, based on their refill 
behavior, and tailored interventions to improve their adherence. By understanding predictive 
characteristics of different adherence behaviors, this can better aid in customizing intervention 
programs to the right patient at the right time. Tailored interventions can then be administered 
with the most appropriate timing to better allocate resources and ultimately improve patient 
outcomes and healthcare costs. 
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1.2 Rationale 
Atrial fibrillation (AF) is a growing health concern with significant complications that 
affects large numbers of US patients, especially older adults.28 Warfarin is the most commonly 
used drug for the prevention of stroke in AF patients in the US.29 Nearly two-thirds of AF 
patients on Medicare have been prescribed warfarin.30 Due to the narrow therapeutic window of 
warfarin and the severity of both treatment failure and overdosing, medication adherence is 
critically important for patients on this anticoagulant. It is well established in the literature that 
poor adherence to warfarin among AF patients is associated with poor health outcomes and 
increased healthcare costs.31 However, medication nonadherence is a major barrier to effective 
warfarin treatment and remains a significant problem despite numerous interventions to improve 
adherence.  
Given the prevalence and consequences of poor adherence to warfarin, there is a need to 
better understand different patterns of adherence behavior and to more accurately identify 
patients likely to be poorly adherent for tailored adherence interventions. No study yet has 
assessed adherence to warfarin in AF patients by classifying patients according to their 
adherence patterns over time. This study aims to classify patients according to their different 
patterns of warfarin adherence over time and to identify predictors of adherence behavior. 
Moreover, this study investigated the impact of each trajectory adherence pattern on subsequent 
clinical outcomes and associated costs. Hence, this study is designed to enable healthcare 
providers and payers to better identify patients with high risk of warfarin nonadherence and its 
associated healthcare costs. Providers and payers will then be better equipped to implement 
interventions tailored to a patient’s specific pattern of adherence. Furthermore, the results of this 
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study can be used to assess the most effective interventions to improve warfarin adherence for 
each trajectory group.  
1.3 Specific Aims 
The study aims to identify and describe warfarin adherence trajectory groups among AF patients 
and to identify predictors associated with membership in each trajectory group. It also aims to 
assess the impact of membership in each adherence trajectory group on clinical outcomes and 
associated healthcare costs. The specific aims of the study are: 
Specific Aim 1: 
A. Identify and describe the trajectory groups of warfarin adherence in patients with AF in 
Medicare population;  
B. Estimate the likelihood of patients belonging to each adherence trajectory; 
C. Identify patients’ characteristics and factors associated with each adherence trajectory. 
Specific Aim 2: 
A. Estimate the rates of hospitalizations related to a stroke or bleeding event (clinical 
outcomes) associated with each adherence trajectory; 
B. Evaluate the association between warfarin adherence trajectory group membership and 
the likelihood of hospitalization due to a stroke or bleeding event. 
Specific Aim 3: 
A. Estimate the AF-related costs for each adherence trajectory group. 
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Chapter 2: Literature Review 
 2.1 Summary of literature on the use of GBTM in medication adherence 
research 
 In order to describe the adherence trajectories of warfarin by using the Group Based 
Trajectory Model (GBTM) and to assess the impact of adherence trajectory groups on clinical 
outcomes and associated healthcare costs, we need to evaluate the literature relating to this topic. 
This was done in two steps. First, we looked at studies that use GBTM in describing medication 
adherence. Second, we evaluated studies that compared GBTM to PDC as an adherence measure. 
A literature review conducted on October 2017 using PubMed/MEDLINE and CINAHL used 
both Mesh terms and key words in appropriate combinations. The search terms were 
combinations of: (group based trajectory modeling OR group based trajectory models OR group 
based trajectory OR trajectory) AND (medication adherence OR "Medication 
Adherence"[Mesh]), (group based trajectory modeling OR group based trajectory models OR 
group based trajectory OR trajectory) AND (fill prescription), (group based trajectory modeling 
OR group based trajectory models OR group based trajectory OR trajectory) AND (medication 
compliance), (group based trajectory modeling OR group based trajectory models OR group 
based trajectory OR trajectory) AND (medication persistence). (Table 1) 
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Titles and abstracts from search result articles were screened using the following inclusion and 
exclusion criteria: 
Inclusion criteria: 
1.  Assess medication adherence 
2.  Apply Group Based Trajectory Model (GBTM) 
3.  Published in English 
Exclusion criteria: 
1.  Apply GBTM to describe trajectories of disease progression 
2.  Review paper, report, or proposal. 
The search on PubMed and CINAHL revealed a total of 208 articles. After eliminating 
duplicates and applying inclusion and exclusion criteria, 23 research articles remained. Out of 
these 23 articles, 19 articles were chosen to be discussed as they assessed medication adherence 
specifically by performing GBTM. The four excluded studies used GBTM to describe patterns of 
disease progression or program intervention (Figure 1). The references of the selected studies 
were reviewed to identify additional studies that meet inclusion criteria. One additional study 
from the references was added to the literature review.  
 The total search resulted in 20 study articles that reported on the use of GBTM in 
describing medication adherence. 
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Table 1: Search term combinations used and resulting number of articles 
Search term combinations Total 
number of 
articles 
Articles 
Meeting 
Inclusion 
Criteria 
((group based trajectory modeling) OR (group based trajectory 
models) OR (group based trajectory) OR (trajectory)) AND 
(("Medication Adherence"[Mesh]) OR medication adherence) 
72  22 
((group based trajectory modeling) OR (group based trajectory 
models) OR (group based trajectory) OR (trajectory)) AND fill 
prescription 
9 3 
((group based trajectory modeling) OR (group based trajectory 
models) OR (group based trajectory) OR (trajectory)) AND 
medication compliance 
69  20 
((group based trajectory modeling) OR (group based trajectory 
models) OR (group based trajectory) OR (trajectory)) AND 
medication persistence 
58  21 
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Total search results (n=208 articles) 
Titles and abstracts reviewed for eligibility 
Articles reviewed for eligibility (n=23) 
Excluded (n= 185) 
duplicate or not met 
inclusion/ exclusion 
criteria 
 
Articles included (n=19 articles) 
Excluded (n= 4) did not 
use GBTM to describe 
medication adherence 
 
 
Total articles included (n=20 articles) 
Included (n= 1) from 
references of the selected 
studies 
 
 
Figure 1: Selection process flow chart 
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Overall the search revealed a total of 20 relevant studies that applied GBTM to describe 
medication adherence patterns among different disease conditions and drug classes. All the 
identified papers were recently published (2010-2017). Six studies were conducted outside the 
United States (one in Taiwan, and five in Europe).32-37 Study populations vary throughout the 
literature, as some studies examined only pediatrics patients,38-40 others included all adult 
patients ≥ 18 years old, and some studies assessed adherence specifically for the elderly 
population. The selected studies assess medication adherence in different disease conditions, 
however, the majority of them focused on populations with cardiovascular 
diseases.22,23,32,33,35,37,41-44 (Table 2) 
Important criteria in comparing studies 
There are several important criteria to consider when comparing between different studies 
that applied GBTM. These are the time period of the study, the number of trajectory groups 
resulting from the analysis, the types of trajectory groups identified, and the drug classes studied. 
Time period of the study. First is the time of the outcome’s measuring period, as it can 
influence the shape of the group trajectories. The time period to measure medication adherence 
varied across studies.  Some captured adherence for a short period only (e.g., four months) while 
others extended over longer periods of time (e.g., six years).  
Number of trajectory groups. Another important criterion to consider when comparing 
between the different trajectory models is the number of groups that resulted from the GBTM. 
The number of trajectory groups describes the level of diversity in the outcome’s patterns (e.g. 
medication adherence patterns). As the number of groups increases, the model can better explain 
the heterogeneity in the outcome trajectories among the study population. On the other hand, a 
large number of groups can be difficult to interpret, so there is always a tradeoff between the 
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accuracy of capturing the underlying reality and the ease of interpreting the analysis. Throughout 
the literature, the number of trajectory groups identified varied between the studies. Overall, the 
optimum number of groups identified in most of the studies was four to six adherence groups. 
However, a study by Lo-Ciganic et al., for hypoglycemic drugs was able to classify patients’ 
adherence patterns using seven trajectory groups.23 At the other extreme, Greenley et al., found 
only two adherence trajectories for patients on thiopurine for Inflammatory Bowel Disease 
(IBD).40  The identification of only two adherence groups may have been due to a small sample 
size (n= 96) which limited the ability to add more groups because group sizes were too small (i.e. 
the proportion of patients in each group should not be less than 5% of total sample).  
Types of trajectory groups. The third criterion to consider when comparing between 
GBTMs across the literature relates to the types of the identified trajectory groups. The most 
common trajectory groups identified in the literature were: “perfect adherence”, “non-
adherence”, and “slow-decline adherence”. The perfect adherent group was described as a steady 
line plotted on a graph over time, where the patients belonging to this group have a persistently 
good adherence level to their medication over the study period. The average PDC value for the 
patients in this group is usually >90 %. Consistently throughout the literature, the highest 
proportion of patients falls in the “perfect adherence” trajectory. On the other hand, the “non-
adherent” group was described in most of the studies as constant low or non-adherence over the 
study period, with less than two prescriptions filled, and can be described in a graph as a low 
steady line. Some of the studies reported that it was hard to distinguish whether the patients who 
belong to this group were truly non-adherent or just discontinued their medication and switched 
to another class.23 The final commonly identified group was the trajectory in which patients 
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started with good adherence and became slowly non-adherent over time. The average PDC for 
this group was 50-60%.  
Studies differed when describing the trajectory groups between perfect adherence and non-
adherence groups. Few studies identified trajectory groups in which patients experienced a very 
rapid decline in their adherence pattern.34,38,41,45-47 In these studies, they included new patients 
who filled at least one prescription of medication. So, a trajectory of very rapid decline can be 
related to the improvement in the disease condition to the point that patients do not require 
treatment any more, or that patients were on a one-time dose and then discontinue treatment. 
This is can be In contrast, a study by MacEwan identified trajectory where the adherence was 
good at first and then declined after a period of time (e.g. after 6 months or 9 months).48 These 
differences in the identified trajectory groups among the studies can be due to several factors 
related to study population, disease characteristics, sample size, and the assigned duration for 
assessing medication adherence (study period). All of these factors can play a role in describing 
adherence trajectory patterns.  
Drug classes studied. Most GBTM studies on patterns of medication adherence limited 
their analysis to a single therapeutic drug class over time which limited the ability to identify 
differences across medications in a single population. An exception was a study by Librero et al. 
that examined and compared adherence trajectories for four different drug classes: beta-blockers, 
ACEIs/ARBs, antiplatelet agents, and statins for discharged patients with congestive heart failure 
(CHF).33 The GBTM showed three different patterns of trajectory for this population that varied 
depending on the drug class. There were five trajectories for the antiplatelet cohort, four 
trajectories for the beta-blocker and ACEI/ARB cohort, and three trajectories for patients on 
statins indicating that adherence trajectories were not homogeneous for CHF discharge patients 
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prescribed different medications. The authors concluded that the GBTM approach better captures 
the dynamic nature of the adherence behavior over time than other traditional measures (e.g., 
PDC). 
Patient Characteristics Associated with Trajectories 
The literature suggests that a deeper understanding of patients’ characteristics associated 
with each trajectory group can help in identifying patients in poor adherent groups and in 
implementing more effective interventions to improve their adherence. Adherence groups may 
vary upon demographic characteristics and benefit differently from alternative intervention 
strategies. In addition, adherence trajectories may diverge based upon patients’ 
characteristics.33,48  
Different studies in the literature identified characteristics associated with poor and 
intermediate adherence trajectories which can serve as a signal for the clinicians to target those 
patients with a suitable intervention at the proper time.  For example, Juarez et al., found that the 
white, Asian, and Pacific Islanders patients with CHF were more likely to have low adherence in 
the first year after discharge compared to black patients.42 Such findings can aid in the targeting 
of patients with the right intervention at the early phase after discharge to ensure better 
adherence behavior. Thus, a useful application of the GBTM rests on its ability to identify 
patients with a high probability of having a poor adherence trajectory and thereby targeting them 
with proper intervention.33  
Some studies examined the association between patients’ demographic and clinical 
characteristics with different adherence trajectories. Age, gender, race, and educational level 
have been found to be associated significantly with adherence trajectories.23,34-36,42,43,49 It has 
been reported that the patients in the lower adherent groups tend to be younger, non-white, males 
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with low educational level. Higher adherent trajectories are more common in older, white 
populations with higher educational level (bachelor’s degree and above). Other studies have not 
found an association between these demographics factors and adherence trajectories.39 This may 
be due to the different characteristics of the study design including: disease population, study’s 
sample size, and study period. 
Other population characteristics have been related to adherence trajectories. Low 
socioeconomic status is associated with lower adherent trajectories.32,34,39,48 Higher copayment 
share is also associated with lower adherent trajectory groups.33 The presence of comorbidities 
has been found to be a strong predictor of low adherence groups.48,50 Many of these 
characteristics are also variables described in theoretical frameworks related to medication 
adherence, such as the Andersen Behavioral Model (ABM).51  
Trajectories and Healthcare Utilization 
Adherence trajectories have been associated with healthcare utilization. Six studies 
examined specifically at the impact of adherence trajectories on healthcare events (e.g., 
hospitalization events, ED visit, disease-related adverse events, or death).22,23,38,48,52,53 They 
found that better adherent trajectories were associated with fewer hospitalization events and a 
lower mortality rate. Mac Ewan et al., used GBTM to stratify schizophrenic patients treated with 
oral Atypical Antipsychotics into groups based on their adherence behaviors.48 They reported 
that patients in the perfect adherent group had fewer ED visits compared to low adherent groups. 
Lo-Ciganic et al., assessed the association between trajectories of hypoglycemic medication 
adherence and risk of ED visit and hospitalization.23 They concluded that low and moderate 
adherent and non-adherent group membership was associated with higher risk of ED visits/ 
hospitalizations in contrast to perfect-adherent trajectory. A study by Winn et al., examined the 
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relationship between adherence trajectories of endocrine therapy and death in women with breast 
cancer.53 They found that patients in rapidly and moderate decline adherence trajectories had 
significantly higher risk of death compared to perfect adherent trajectories. Furthermore, 
Franklin et al., studied the association between trajectories of statin adherence and cardiovascular 
events, and they concluded that lower adherent groups were associated with higher risk of 
cardiovascular events compared to perfect adherent trajectories.22 A study by Modi et al., 
evaluated the relationship between adherence trajectories of antiepileptic drugs in a pediatric 
population with seizure outcomes, and they reported that patients with unstable adherence levels 
have a higher rate of seizures.38 Similarly, a study by Gueorguieva et al., assessed the 
relationship between adherence trajectories of pharmacological treatment (naltrexone, 
acamprosate), behavioral interventions, and drinking outcomes and concluded that the perfect-
adherent group experienced less drinking compared to non-adherent groups.52 
Predictive Validity of GBTM 
Several published studies in the literature have examined the predictive performance of 
GBTM compared to conventional measures (e.g. PDC). Six out of seven studies showed GBTM 
to be superior in capturing longitudinal adherence patterns than PDC.22,23,32,44,50,53 A study by 
Hargrove et al., compared adherence trajectories identified by GBTM to conventional adherence 
measures (proportion days covered (PDC), medication possession ratio (MPR) and reported that 
a six group trajectory model better distinguished between adherent and non-adherent months 
than the PDC or PMC, especially for patients with inconsistent adherence patterns.44 A study by 
Aarnio et al., examined the relationship between socioeconomic position (SEP) and statin 
adherence for men compared to women using GBTM and conventional measures (PDC<80%).32 
They found that GBTM provided a better description of adherence behavior and more 
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comprehensive details in differentiating between adherence groups.  Winn et al., investigated the 
association between endocrine therapy adherence trajectories and mortality compared to the 
conventional PDC measure.53 They found that both measures show significant association 
between adherence and mortality; however, the hazard of survival when using PDC was very 
small (hazard ratio (HR) 1.21) and did not distinguish between different adherence groups as 
seen when using GBTM.  Lo Ciganic et al., examined the impact of adherence trajectories in 
predicting diabetes-related hospitalization and ED visits compared to conventional PDC 
measures.23 They concluded that the adherence trajectories in the multi-variants model showed 
better prediction for the clinical outcomes compared to a dichotomous PDC measure. Similarly, 
Franklin et al., reported that the use of statin adherence trajectories predicts cardiovascular 
events better than the traditional PDC ≥ 80% threshold.22 Finally, Li et al., compared biological 
treatment adherence patterns using GBTM and PDC in patients with psoriasis.50 The GBTM 
identified four trajectory patterns. In order to compare the two measures, an equivalent number 
of groups were constructed from the same cohort of patients using the PDC measures in the 
following way: Group 4 (PDC≥ 75%), Group 3(50% <PDC <75%), Group 2 (25%< PDC< 
50%), and Group 1 (PDC ≤25%). The authors reported that GBTM and PDCs were similar in 
categorizing patients in the extreme groups (perfect-adherent and non-adherent groups).  
However, for the patients in the intermediate groups, there was a difference in the longitudinal 
adherence patterns when using GBTM compared to PDC. The use of GBTM resulted in a better 
classification of adherence patterns compared to the traditional PDC measure. 
Only one study has reported that GBTM might not accurately reflect adherence behavior.37 
In this study, the authors evaluated the predictive validity of GBTM in patients with 
hypertension. They identified four trajectories for hypertensive medication adherence for 905 
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patients. The predictive validity was measured by assessing relationships between trajectory 
groups and blood pressure (BP) measurements. They did not find association between adherence 
trajectories and BP measurements, although they offered several explanations for their results. 
First, the result could be related to the “white coat adherence effect”, in which patients exhibit 
better adherence behavior in the day prior to the clinic visit.  The theory posits that since patients 
already knew that they would undergo a BP measurement during their visit, they adhered to their 
medication before the visit. Second, blood pressure was only measured a single time, which 
might make it less reliable. Third, the small sample size restricted the generalizability of the 
study results. 
Summary of Findings 
Based on this literature review, there are important points to consider when applying GBTM. 
GBTM assumes that there are an infinite number of patterns that can model differences between 
the individuals in the real world.54 Therefore, when starting to build a GBTM, there are an 
almost unlimited numbers of possible trajectory groups to describe the different adherence 
patterns seen with the real-world patients.33  
Depending on the criteria used for fitting the final model, the number of trajectory groups is 
identified using the following methods: 1) model fit using Bayesian information criteria (BIC), 
where a lower value indicates better fit; 2) the proportion of patients in each group is not less 
than 5% of total sample; and 3) Nagin’s criteria for model adequacy.33 Then, after identifying the 
appropriate number of trajectory groups, the patients in the cohort are classified into these groups 
based on their membership probabilities (that is, group membership is determined by the highest 
likelihood of belonging to a certain trajectory group). Once classified, the GBTM assumes that 
patients in groups will have similar patterns of adherence over time.  
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The literature appears to show that trajectory group classification is most beneficial for 
patients who are somewhere between perfect adherence and non-adherence. GBTM is no better 
than PDC measures for these patients. The value of GBTM lies in understanding adherence 
patterns in intermediate groups (e.g., slowly declining and low adherence then rapid increase 
groups). PDC measures lump patients into single groups while GBTM identifies more adherence 
patterns. For instance, a study by Mardby et al., found PDC classified half of the study 
population as non-adherent.34 In contrast, GBTM found one third of the study population non-
adherent within the first few months after initiating the therapy because it differentiated non-
adherence according to the time it occurred. The ability to more finely differentiate patient 
adherence over time is why the GBTM has the advantage over PDC measurement.   
It is important to understand that the main goal of GBTM is to describe and summarize 
different patterns, and to simplify the complexity of the real-world situation in order to better 
understand differences between patients’ behaviors.54 Thus, the summarization of the real-world 
differences means that there must be some approximation for the simplicity of understanding and 
interpretations. The key point is that the individuals belonging to each trajectory group are not 
identical, rather similar in many aspects. 
GBTM is an innovative approach that can be used to describe adherence patterns by taking 
into account the dynamics of medication adherence and changes in adherence behavior over 
time. GBTM can be clinically useful for healthcare providers and payers in tailoring adherence 
interventions to better allocate resources and enhance patients’ outcomes and overall healthcare 
costs.  
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Table 2: Summary of identified studies 
Authors Objective Population Type of 
treatment 
Length of 
study 
period 
Country Sample 
size 
Trajectory group Clinical outcomes Conclusion 
1. Dillon et al., 
201737 
 
1.Characterize 
adherence to 
antihypertensive 
medication  
2. Test predictive 
validity of GBTM 
against blood pressure 
measurement 
Patients aged 
≥ 65 years old  
Antihypertensive 1-year Republic 
of 
Ireland  
 
905  
 
1.Perfect adherence 
2.High adherence 
3.Moderate non-adherence 
- GBTM identified 3 
trajectories. 
However, did not 
show predictive 
validity with BP 
measurement 
2. Hargrove et 
al., 201744 
1.Use GBTM to 
identify 
antihypertensive 
adherence trajectories 
2.Comapre adherence 
trajectories to 
traditional adherence 
measures 
3. Identify patients 
characteristics 
associated with 
adherence trajectories 
Medicare 
patients aged 
≥ 65 years old  
Antihypertensive 1-year US 282,520  
 
1.Perfect adherence 
2. Rapid decline, then increase 
3. Moderate decline, then 
increase 
4. Moderate decline  
5. Rapid decline 
6. Very rapid decline 
 
- GBTM is an 
effective method to 
identify patterns of 
medication 
adherence compared 
to PDC 
3.MacEwan et 
al., 201648 
1. Identify adherence 
trajectory for oral 
atypical antipsychotics 
(OAA) 
2. Identify associated 
factors 
Adult 
schizophrenia 
patients 
Oral atypical 
antipsychotic 
1-year US 29,607  
 
1. Perfect adherence 
2. Decline after 3 months  
3. Decline after 6 months 
4. Decline after 9 months 
5. Rapid decline, then increase 
after 6 months 
6. Very rapid decline 
Psychiatric inpatient 
admission and ED 
visit 
-Adherence patterns 
identified by GBTM 
are more varied than 
research based on 
PDC 
-Lower adherence 
trajectories 
associated with 
higher ED visits 
4.Aarnio et 
al.,201632 
1. Identify adherence 
trajectory of statin 
2. Examine 
association between 
SEP and adherence 
trajectories 
Patients aged 
45 to 75 years 
 
Statin 18-months Finland 116,846  
 
1. Perfect adherence 
2. High adherence 
3. Rapid decline, then increase 
4. Moderate decline  
5. Rapid decline 
6. Very rapid decline 
- SEP is associated 
with low adherence 
groups. Overall, 
GBTM provide 
insight to dynamics 
of adherence 
behavior 
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Table 2: Continued 
 
Authors Objective Population Type of 
treatment 
Length of 
the study 
period 
Country Sample 
size 
Trajectory group Clinical outcomes Conclusion 
5.Libero et al., 
201633 
1. Identify adherence 
trajectory for ACEI, 
statin BB, and 
antiplatelet 
2. Identify associated 
factors 
Patients 
discharged 
with coronary 
heart disease 
(CHD) 
 
ACEI, statin BB, 
and antiplatelet 
 
9-months Spain 7,462  
 
1.Perfect adherence 
2. Low adherence, then 
increase 
3. Moderate decline, then 
increase 
4. Moderate decline  
5. Rapid decline 
 
- GBTM identified 
distinct adherence 
trajectories for 
difference preventive 
medication for CHD. 
It showed advantage 
over traditional 
measure  
6.Mårdby et 
al., 201634 
1. Identify adherence 
trajectory of 
antidepressants  
2. Identify associated 
factors 
Patients aged 
18–85 years 
Citalopram 24-months Sweden 54,248  
 
1. Perfect adherence 
2. Moderate decline 
3. Rapid decline, then increase 
4. Rapid decline 
5. Very rapid decline 
- - GBTM identified 5 
distinct patterns 
-low adherence 
trajectories 
associated with lower 
SEP 
7. Lo-Ciganic  
et al., 201623 
1. Identify adherence 
trajectory of oral 
hypoglycemic 
2. Identify associated 
factors 
3. Examine association 
with clinical events 
Patients aged 
18–64 years 
with diabetes 
(DM)  
Oral 
hypoglycemic 
medication 
1-year US  16,256  
  
1. Perfect adherence 
2. High adherence  
3. Moderate decline 
4. Moderate non-adherence 
5. Rapid decline, then increase 
6. Rapid decline 
7. Very rapid decline  
1. DM related ED 
visit/hospitalization 
2. All cause ED 
visit/hospitalization 
Lower adherence 
trajectories 
associated with 
higher 
ED/hospitalization 
events 
8. Winn et al., 
201653 
1. Identify adherence 
trajectory of ET 
2. Identify associated 
factors 
3. Examine association 
with mortality 
Women with 
breast cancer  
Endocrine 
therapy (ET) 
1-year US  9,492  
 
1. Perfect adherence 
2. Slow decline 
3. Rapid decline, then increase 
4. Moderate decline 
5. Rapid decline 
 
Mortality Low adherence 
groups associated 
with higher mortality 
rate 
9. Chen et al., 
201635 
1. Identify adherence 
trajectory of 
hypoglycemic 
2. Identify associated 
factors 
Patients aged 
≥ 18 years 
type 2 
diabetes 
Oral 
hypoglycemic 
medication 
Six-years Taiwan  12,123  
 
1. Perfect adherence 
2. Moderate adherence, then 
increase 
3. Moderate decline 
4. Low adherence, then 
increase 
 
- GBTM help in 
identifying 
heterogeneity of 
medication adherence 
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Table 2: Continued 
 
 
  
Authors Objective Population Type of treatment Length of 
the study 
period 
Country Sample 
size 
Trajectory group Clinical outcomes Conclusion 
10. Franklin et 
al., 201541 
Identify adherence 
trajectory of statin 
Patients aged 
≥ 65 years old  
Statin 1-year US  77,703  1.Perfect adherence 
2. Moderate adherence  
3.  Rapid decline, then increase 
4.  Moderate decline, then 
increase  
5.  Rapid decline 
6. Very rapid decline 
- Initial adherence 
behavior associated 
with better future 
adherence  
11.Newman-
casey et al., 
201549 
1. Identify 
adherence trajectory 
of glaucoma 
medication 
2.  Identify 
associated factors 
Patients ≥40 
years old 
treated for 
glaucoma  
 
Glaucoma 
medication 
4-years US 1,234  1. Perfect adherence 
2.  Moderate non-adherence 3. 
Moderate decline 
4.  Low adherence, then 
increase 
5. Rapid decline  
- Adherence patterns 
for first year, had 
great impact on 
future adherence 
behavior 
12.Juarez et al., 
201542 
1. Identify 
adherence trajectory 
of ACEI 
2.  Identify 
associated factors  
Patients with 
Congestive 
Heart failure 
(CHF)   
ACEI 1-year US 10,986  1.Perfect adherence  
2.  Moderate decline 
3.  Low adherence, then 
increase 
4. Rapid decline  
 
- Patients factors 
associated with low 
adherence trajectories 
can be used to target 
interventions 
13. Franklin et 
al., 201522 
1. Identify 
adherence trajectory 
of statin 
2. Examine 
association with 
clinical events 
Patients in the 
UnitedHealth 
Optum 
Research 
Datamart, 
aged 35-64 
years  
 
Statin 1-year US 519,842  1.Perfect adherence 
2. Rapid decline then increase 
3. Moderate decline  
4.  Moderate decline, then 
increase  
5. Rapid decline  
6. Very rapid decline 
 
Hospitalization for 
an acute coronary 
event, 
revascularization, 
cerebrovascular 
event, or heart 
failure 
Adherence 
trajectories predicts 
future clinical 
outcomes better than 
PDC 
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Table 2: Continued 
  
Authors Objective Population Type of 
medication 
Length of 
the study 
period 
Country Sample size Trajectory group Clinical outcomes Conclusion 
14. Li et al., 
201450 
1. compares GBTM 
and PDC  
2. identify the clinical 
and demographic 
factors associated 
with adherence 
groups  
 
Patients >18 
years old with 
Psoriasis  
 
Treated with 
at least one 
biologic:  
etanercept, 
adalimumab, 
ustekinumab, 
and 
infliximab 
1-year US 3,249  
 
1.Perfect adherence 
2.Moderate non-adherence 
3.Moderate decline 
4.Rapid decline  
 
- GBTM is better in 
capturing dynamic of 
adherence behavior 
than PDC 
15. Modi AC et 
al., 201438 
1.Identify adherence 
trajectory of 
antiepileptic drugs 
2.Examine 
association with 
seizure outcomes 
Children 
diagnosed 
with epilepsy  
Antiepileptic 
drugs 
2-years US 109  1.  Perfect adherence  
2.  Slow decline 
3. Rapid decline, then 
increase 
4. Very rapid decline 
 
 
 
Seizure outcomes Low adherence 
trajectory associated 
with higher seizures 
16. Greenley et 
al., 201440 
1. Identify adherence 
trajectory of 
thiopurine  
2.  Identify associated 
factors 
Adolescents 
with 
Inflammatory 
Bowel Disease 
(IBD) 
Thiopurine 6-months US 96  1. Perfect adherence 
2.  Moderate non-adherence  
- Nearly 60% of 
participants are 
perfectly adherent 
17.Franklin et 
al., 201343 
1. Identify adherence 
trajectory of statin 
2.  Identify associated 
factors 
Patients 
initiating 
statin in CVS 
Caremark 
Statin 15-months US 264,789  1. Perfect adherence 
2. Rapid decline then 
increase 
3. Moderate decline  
4.  Moderate non-adherence  
5. Rapid decline  
6. Very rapid decline 
 
- GBTM summarized 
adherence patterns 
better than traditional 
measures 
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Table 2: Continued 
Authors Objective Population Type of 
treatment 
Length of 
the study 
period 
Country Sample size Trajectory group Clinical outcomes Conclusion 
18.Gueorguieva  
et al., 201352 
1. Identify adherence 
trajectory of 
medication adherence 
and participation in 
Combined Behavioral 
Intervention  
2.Estimate effects of 
adherence trajectories 
on drinking outcomes  
Abstinent 
alcohol 
dependent 
patients 
enrolled in 
COMBINE 
study 
 
Naltrexone, 
Acamprosate 
4-months US 1,174  1. Perfect adherence  
2. Moderate non-adherence 3. 
Rapid decline  
 
Percent days 
abstinent (PDA) and 
percent heavy 
drinking days 
(PHDD)  
 
Lower adherence 
trajectories associated 
with worse drinking 
outcomes 
19. Modi AC et 
al., 201139 
1. Identify adherence 
trajectory of 
antiepileptic drugs  
2.  Identify associated 
factors 
Children 
diagnosed 
with epilepsy  
Antiepileptic 
drugs 
6-months US 124 patients 1.  Perfect adherence  
2. slow decline  
3. Moderate non-adherence 
4. Moderate decline  
5. Rapid decline  
- GBTM identified 5 
patterns for 
antiepileptic 
medication adherence, 
and were significantly 
associated with SEP 
20. Glass  
et al., 201036 
1. Identify adherence 
trajectory of 
combination 
antiretroviral therapy 
(cART)  
2.Identify associated 
factors 
HIV adult 
patients 
Combination 
antiretroviral 
therapy 
(cART)  
 
6-years Switzerlan
d 
6,709 
patients 
1. Moderate non-adherence 
2. Moderate decline 
3 Low adherence, then 
increase 
4. Low adherence 
- Substance and alcohol 
consumption, 
psychiatric treatment, 
and loss of social 
support were 
significantly 
associated with lower 
adherence trajectories  
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2.2 Gaps in the literature 
This literature review found that GBTM is considered a better approach to capture 
longitudinal patterns of medication adherence compared to conventional measures. Moreover, 
the literature indicates that GBTM can provide more details on characteristics of patients who are 
likely to be non-adherent.  Based on published results, the GBTM approach can better predict 
clinical outcomes compared to conventional measures.  
No study has yet applied GBTM to capture long-term adherence trajectories of warfarin in 
AF patients. Moreover, no published study has used GBTM to describe key characteristics of 
different patterns of warfarin adherence. This study is the first to describe warfarin adherence 
patterns using GBTM and to assess relationships between adherence trajectories, hospitalization, 
and healthcare-related costs. The results of this study can help in identifying AF patients who are 
more likely to be non-adherent to warfarin therapy and to have higher healthcare utilization, 
allowing healthcare professionals to target them with suitable interventions. 
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2.3 Conceptual framework 
In this study, the Andersen Behavioral Model (ABM) was used to evaluate the relationship 
between medication adherence and health outcomes. This model is useful in identifying factors 
related to warfarin adherence and explaining the association between adherence and health 
outcomes. The model was first developed to better predict utilization of health services and 
behaviors and has since been adapted to better understand medication adherence.51,55,56 The 
ABM classifies the predictors of health behavior into 3 main components: predisposing factors, 
enabling factors, and need factors. The predisposing factors are those factors that explain an 
individual’s tendency toward certain behavior and include demographic, social structure, and 
health belief variables. Enabling factors are the individual resources that promote or inhibit 
certain behaviors, including personal and community factors.  Need factors relate to an 
individual’s assessment of their need to adopt a health behavior and include perceived factors 
(e.g. perception of illness) and evaluated factors (e.g. illness severity). In the ABM, these three 
components affect health behavior which, in turn, impacts health outcomes. Moreover, in this 
model, the health outcomes also have an impact on the predisposing, enabling, and need factors 
as well as overall health behavior. 
In this study, the ABM has been modified to fit medication adherence in older populations 
based on the published literature (Appendix A).51,55 The predisposing factors in the adherence-
specific ABM model include demographic characteristics (age, gender, and race), in addition to a 
social factor, educational level. Furthermore, two additional factors have been added to the 
original model: treatment characteristics (dosing, regimen complexity, INR monitoring) and 
disease characteristics (cognitive impairment and depression). These two factors were added as 
they have been found to significantly impact medication adherence behavior in older adults.51,57 
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The enabling factors in this model include personal-level factors, namely, insurance status and 
income, as well as a community-level factor, specifically, social support. The need factors are 
comorbidity, illness severity, and AF-specific symptoms. Additionally, anticoagulant clinic 
participation has been added to the original model given its importance in explaining warfarin 
adherence behavior. Each of these factors has previously been identified as a significant 
predictor for warfarin adherence in older adults.57 
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Chapter 3: Method 
This chapter explains the methodology used to address specific aims 1, 2, and 3. It describes data 
sources, study design, study population, variables, outcomes measures, and statistical analyses. 
Approvals  
The proposal for this study was approved by the Virginia Commonwealth University institutional 
review board (IRB) under expedited review. In addition, the study was also approved by the 
Centers for Medicare and Medicaid Services (CMS).  
Data Source: 
The data employed for this study was obtained from the CMS. The study used 2008-2010 
Chronic Condition Data Warehouse (CCW) Medicare files, which was provided via the Research 
Data Assistance Center (ResDAC). Medicare is a federal insurance program that is offered for 
people aged 65 years or older, end stage renal disease patients, and patients with disabilities.  
The population of interest for this study was AF patients treated with warfarin. The majority 
of AF patients in the database are ≥65 years of age.  According to the CCW sample size 
estimator, five percent of all the Medicare beneficiaries were diagnosed with AF, and almost two 
third of AF patients were being treated with warfarin.58 Medicare data were used in this study as 
this resource is considered a good source for information on the elderly population. Moreover, 
claims data are known to be associated with lower recall bias and self-reporting bias compared to 
survey data.   
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In this study, a 5% random sample of all Medicare beneficiaries in 2008 to 2010 was used to 
provide information on health services and associated billings issued under Medicare Part A 
(inpatient), Medicare Part B (physician visits, outpatient care, ED visits) and Medicare Part D 
(pharmacy drug claims). A number of different Medicare files were employed to address the 
objectives of this study. The beneficiaries’ information linked across files using a unique coded 
patient identifier to prevent patient identification (BENE_ID). The Master Beneficiary Summary 
file (MBSF) was used to obtain patients’ demographic and enrollment information. The MBSF 
Chronic Condition and Other Chronic Condition files were used to identify different AF patients 
and different comorbid conditions. The beneficiary was flagged with a specific condition in the 
Chronic Condition and Other Chronic Condition files based on the existence of one inpatient or 
at least two outpatient claims. Files of Part A contain all claims related to hospital services and 
inpatient services and was used to identified all hospitalization events related to AF and to 
calculate associated costs. Files from Medicare Part B contain all hospital outpatient and 
anticoagulant clinic claims. Medicare Part D events file (PDE) and drug characteristics file 
contain information regarding prescription drug claims, including national drug code (NDC), 
date of prescription refill, quantity supply, days of supply. These claims were used to identify 
patients who are treated with warfarin and to assess adherence trajectories. The files and the 
variables that have been used are shown in the tables below. 
 
		 34	
Table 3: Master Beneficiary Summary File (MBSF) 
SAS Variable Name Description 
BENE_ID  An unique encrypted beneficiary identification number that was 
used to link the beneficiaries across files  
AGE  Beneficiary’s age at the end of the year  
SEX  Beneficiary’s gender  
RACE  Beneficiary’s race was categorized as White, Black and Others  
DEATH_DT Beneficiary’s date of death was used to identify patients who were 
alive from baseline through the measurement period 
A_MO_CNT  Month counts of part A coverage, used to identify beneficiaries 
with continuous enrollment in part A 
B_MO_CNT  Month counts of part B coverage, used to identify beneficiaries 
with continuous enrollment in part B 
PTD_MO Month counts of part D coverage, used to identify beneficiaries 
with continuous enrollment in part D 
HMO_MO  Total number of months of HMO coverage, used to identify 
beneficiaries with fee-for–service versus HMO coverage 
PTD_CNTRCT_ID (1-
12) 
A unique encrypted contract ID, used to identify patients with 
stand-alone prescription (i.e. no MA-PD beneficiary)  
CST_SHR_GRP_CD(1-
12) 
Cost share group code, used to identify beneficiaries with low 
income subsidy as proxy for income variable  
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Table 4: Inpatient and outpatient files 
 
 
 
SAS variable Name Description  
BENE_ID  An unique encrypted beneficiary identification number that was 
used to link the beneficiaries across files 
CLM_ID  Unique encrypted identifier number for claims used to identify 
duplication of claims  
 
CLM_THRU_DT Claim date 
 
PMT_AMT  Amount of payment made from the Medicare for the services 
covered by claim  
 
UTIL_DAY  Number of days utilized by claims, used in calculating amount 
paid by Medicare not included in the claim payment amount  
 
PER_DIEM  Pass through amount not included in the claim payment amount  
 
PRPAYAMT  Amount paid by primary payer other than Medicare 
 
DED_AMT 
 
Beneficiary deductible amount for inpatient service 
 
COIN_AMT  Beneficiary coinsurance amount for inpatient service 
 
BLDDEDAMT 
 
Beneficiary blood deductible liability amount  
 
ADMTG_DGNS_CD  Beneficiary's initial diagnosis at admission ICD-9-CM code 
 
PRNCPAL_DGNS_CD  Primary diagnosis ICD-9-CM code  
 
ICD_DGNS_CD1-25  Claim diagnosis code 
 
ADMSN_DT Claim admission date 
 
HCPCS_CD 
 
The Health Care Common Procedure Coding System (HCPCS) 
is used to identify anticoagulant services 
 
CLM_LINE_NUM Claim line number, used to identify line outpatient claims 
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 Table 5: Part D Event (PDE) File 
 
SAS variable Name Description  
BENE_ID An unique encrypted beneficiary identification number that was used to 
link the beneficiaries across files 
PDE_ID  An unique encrypted Part D identification claim number used to 
identify duplicate claims  
SRVC_DT  Prescription service date 
BENEFIT_PHASE Benefit phase of the part D event, used to identify beneficiary in the 
coverage gap 
PTPAYAMT  Amount paid by patient for claim 
CPP_ Amount paid by Medicare for claim 
GNN / PRDSRVID Product service ID by NDC 
DAYSSPLY Number of days' supply of the drug, used to measure warfarin 
adherence 
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Table 6: MBSF Chronic Condition and Other Chronic Condition Files 
SAS variable Name Description  
BENE_ID  An unique encrypted beneficiary identification number that was 
used to link the beneficiaries across files 
AMI  Acute Myocardial infarction  
ALZ  Alzheimer’s disease 
ATRIAL_FIB Atrial Fibrillation  
COPD Chronic Obstructive Pulmonary Disease  
CHF Congestive Heart Failure 
DIABETES   Diabetes  
RA_OA  Rheumatoid Arthritis  
STRKETIA Stroke /Transient Ischemic Attack (TIA) 
CNCRBRST  Breast Cancer 
CNCRCLRC  Colorectal Cancer 
CNCRPRST  Prostate Cancer 
CNCRLUNG  Lung Cancer  
CNCRENDM Endometrial Cancer  
DEPRESSN  Depression  
HYPERT Hypertension  
HIVAIDS_MEDICARE HIV/AIDS 
BIPL_MEDICARE  Bipolar disorder 
LIVER_MEDICARE  Liver Disease/Cirrhosis and other liver conditions exclude 
Hepatitis 
SCHIOT_MEDICARE  Schizophrenia and other psychotic disorders 
PVD_MEIDCARE Peripheral Vascular Disease 
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Study design: 
This is a retrospective cohort study examining the adherence behaviors and healthcare 
utilization of AF patients treated with warfarin using Medicare claims data from 2008 to 2010. 
The index period defined for the study was July 1, 2008 – December 31, 2009 and the date of the 
first warfarin prescription claim received in the index period was assigned as the index date for 
warfarin users. A pre-index period was defined as the six months period prior to the index date. 
A pre-index period is important to identify baseline characteristics and incident warfarin users. 
The incident users were defined as those patients who did not have a prescription claim for 
warfarin in the six months prior to the index date. Patient prescription refill claims were followed 
for 12 months from the index date to assess warfarin adherence. Any additional period after the 
12-month follow-up period was used to measure AF-related clinical outcomes (AF-related 
hospitalizations) and to calculate AF-associated costs (Figure 2). 
 
 
 
 
 
 
 
 
	
Pre-index period 
(6 months not using 
anticoagulants) 
	
Index period 
(18 months identify warfarin 
prescription and measure adherence)  
	
Post index period (identify 
first hospitalization) 
Figure 2: Study timeline 
	
First 6 months used 
to identify first 
warfarin 
prescription 
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Population and setting: 
From the Medicare 5% sample population, all patients ≥ 65 years old with Atrial 
Fibrillation (AF) and treated with warfarin between July 1, 2008 and December 31, 2010 were 
eligible for inclusion in this study. Patients with AF were identified using the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes from 
principle diagnosis, admitting diagnosis or any of the 25 ICD diagnosis variables in the inpatient 
(Part A), outpatient (Part B) claims, or the chronic condition file. Any patient who had at least 
one inpatient claim or two outpatient claims for AF in any of the claim fields was included in the 
study (ICD-9-CM codes 427.31 is associated with AF). The National Drug Codes (NDC) of 
warfarin were used to identify patients on warfarin treatment. Any AF patient who had at least 
two warfarin prescription claims from July 1st 2008 to December 31, 2009 in the claims data was 
included in the study. A minimum of two claims of warfarin was chosen to exclude patients who 
might be given one prescription of warfarin and then discontinued treatment.   
Only the beneficiaries with fee-for-service benefits and continuous enrollment in the 
Medicare Parts A, B and D throughout the study period were included in the study. The 
continuous enrollment was defined as having 12 months of part A, B, and D access, as 
represented in the variables A_MO_CNT, B_MO_CNT and PTD_MO, for each year from 
January 1, 2008 to December 31, 2010. The beneficiaries with fee-for-service benefits were 
identified by using the HMO_MO and PTD_CNTRCT_ID variables from the MBSF files. The 
fee-for-service beneficiaries were defined as those with zero months of HMO coverage and who 
were enrolled in “Stand Alone Prescription Drug Plan” from January 1, 2008 to December 31, 
2010. Patients were excluded: 1) their encounter was for palliative care, including end of life 
care, hospice care and terminal care (identified by ICD-9_CM V66.7) or 2) if they were 
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diagnosed with metastatic cancer as those beneficiaries have different drug utilization patterns 
which affect their adherence behavior (using ICD-9-CM code 196-199.1); or 3) patients enrolled 
in managed care plans.  
Variables:  
The relevant factors presented in the conceptual model were included as potential 
confounders in the different analyses in this study. As previously discussed, those factors have 
been shown to impact medication adherence and healthcare utilization in the elderly. Patient-
related variables, including age, gender, and race, were identified from the Beneficiary summary 
file (MBSF) at the baseline period. The Medicare data used in this study does not contain 
information regarding a beneficiary’s income. The low income subsidy (LIS) variable was used 
as a proxy for income. This Medicare program offers the medications at reduced cost for the 
beneficiaries who are eligible based on income, family size, and household resources. The LIS 
was used in different studies as proxy for the income variable.44,59 The prescription-related 
variables, including number of unique medications, were identified from the PDE and drug 
characteristics file. The INR monitoring and anticoagulant clinic access were identified by using 
the corresponding Current Procedural Terminology (CPT) code in outpatient files. Disease 
characteristic variables, including Charlson Comorbidity Index (CCI), CHADS2 (as an indicator 
of stroke risk), depression and presence of cognitive impairment during the baseline period (six 
months before the index date) were identified from Chronic Condition and Other Chronic 
Condition files, inpatient claims, or outpatient claims using corresponding ICD-9-CM codes. 
Due to limitations of Medicare dataset, the social support and health belief factors of the 
Andersen Behavioral Model were not assessed in this study.  
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Age: 
      The age variable was identified from the MBSF file and was coded as a continuous variable 
based on the age of the beneficiary in the baseline period. 
Gender: 
The gender variable was identified from the MBSF file and was categorized as male or 
female. 
Race: 
       The race variable was identified from the MBSF file and was coded as “White”, “Black”, or 
“Others”. 
Income: 
       Eligibility for the low income subsidy (LIS) program (as a proxy for income of beneficiary) 
was identified using the cost share group variable (CST_SHR_GRP_CD) in the MBSF file. The 
cost share code variable indicates the beneficiary’s part D low income subsidy cost sharing group 
for each month of the year (from January- December). The LIS program for the Medicare Part D 
provides subsidies that lower or eliminate Part D premiums and defines cost sharing for certain 
low income beneficiaries. The LIS variable was identified for each beneficiary in the study 
cohort in the baseline period and was coded as a categorical variable indicating whether or not 
the beneficiary was eligible for the LIS program or not. 
Charlson Comorbidity Index (CCI): 
       The CCI has been used in many retrospective claims studies as an indicator of patient 
comorbid conditions, and mortality risk.60 This variable was coded as a continuous variable and 
calculated for each beneficiary in the study based on the existence of 17 comorbid conditions.61 
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The conditions were identified based on the presence of corresponding ICD-9- CM codes in the 
inpatient claims, outpatient claims, the Chronic Conditions file, and the Other Chronic 
Conditions CCW files (Table 7). For each beneficiary, corresponding scores were summed based 
on the presence of comorbid conditions and assigned as a CCI score. For example, a patient with 
peptic ulcer (CCI score of 1) and Myocardial Infarction (CCI score of 1) would have been 
assigned a CCI score of 2.  
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Table 7:Conditions included in Charlson Comorbidity Index (CCI) 
Condition  ICD-9-CM codes Score  
Myocardial infarction 410.x, 412.x 1 
Congestive heart failure (CHF) 428.x 1 
Peripheral vascular disease   441.x, 443.9, 785.4  1 
Cerebrovascular disease 430-438  1 
Dementia 290.x 1 
Chronic obstructive pulmonary disorder 490-496, 500-505, 506.4  1 
Rheumatologic disease 714.81, 725, 710.0, 710.1, 710.4, 
714.0- 714.2  
1 
Peptic ulcer 531.0-531.7, 532.0-532.7, 533.0-
533.7, 534.0-534.7 ,534.9 
1 
Mild liver disease and cirrhosis  571.2, 571.4x-571.6 1 
Diabetes 250.0-250.3, 250.7  1 
Paralysis 342.x, 344.1  1 
Diabetes with chronic complications  250.4-250.6  2 
Renal disease 582.x,585, 586, 588.x, 583.0-583.7  2 
Any malignancy include leukemia or 
lymphoma 
140-172.9, 174-195.8, 200-208.9  2 
Moderate or severe liver disease 572.2-572.8, 456.0-456.21  3 
AIDS 042-044  6 
Metastatic solid tumor 196-199.1  6 
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CHADS2-VASc score:  
The CHADS2-VASc score was used as an indicator of stroke risk.  The CHADS2-VASc 
score  is a validated scheme for stratifying stroke risk in AF patients.
 
It is a number from 0 to 9, 
where 0 is lowest risk and 9 is highest risk. Stroke risk is calculated depending on the presence 
of the following risk factors: Congestive Heart Failure (CHF), Hypertension, age ≥75, Diabetes 
Mellitus (DM), history of stroke or TIA symptoms, vascular disease, age 65-74, and being 
female. Presentation of each risk factor adds 1 point to the total the CHADS2-VASc score with 
the exception of history of a previous stroke and age ≥75 which add 2 points (table 8). The 
conditions were identified using inpatient claims, outpatient claims, the Chronic Conditions file, 
and the Other Chronic Conditions CCW files using corresponding ICD-9- CM codes. The 
variable CHADS2-VASc score was coded as a continuous variable. 
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Table	8:	CHADS2-VASc	score	for	stratifying	stroke	risk	in	AF	patients	
Criteria ICD-9-CM codes Value 
History of Congestive Heart Failure (CHF) 428.x  +1 
History of Hypertension  401.x-405.x +1 
Age ≥ 75 - +2 
History of Diabetes Mellitus (DM) 250.00, 250.01, 250.02, 250.03, 
250.10, 250.11, 250.12, 250.13, 
250.20, 250.21, 250.22, 250.23, 
250.30, 250.31, 250.32, 250.33, 
250.40, 250.41, 250.42, 250.43, 
250.50, 250.51, 250.52, 250.53, 
250.60, 250.61, 250.62, 250.63, 
250.70, 250.71, 250.72, 250.73 
+1 
Stroke or TIA* Symptoms Previously 433.x1, 434.x1, 435.x, or 436 +2 
Vascular disease (e.g. peripheral artery 
disease, myocardial infarction, aortic 
plaque) 
410.x, 412.x, 441.x, 440.0, 
440.1, 440.2, 440.20, 440.21, 
440.22, 440.23, 440.29, 440.4, 
443.80, 443.81, 443.82, 443.89, 
443.9, 785.4 
+1 
Age 65–74 years - +1 
Gender (female) - +1 
 
Depression: 
Depression was identified from the Chronic Condition and Other Chronic Condition files 
inpatient claims, outpatient claims using corresponding ICD-9- CM code (296.2, 296.3, 311.xx). 
This variable was coded as a dummy variable indicating whether or not the beneficiary had 
received a diagnosis of clinical depression. This is an important variable to include in the 
analysis as depression has been found to affect medication adherence behavior.62,63 
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Cognitive impairment and mental disorders: 
This variable denotes the presence of different mental and cognitive conditions. It was 
coded as a dummy variable indicating whether or not the beneficiary had any of the following 
conditions: dementia (including Alzheimer’s disease), bipolar disorder, or schizophrenia. These 
conditions were considered in the analysis as they have been shown to have an impact on 
patients’ medication adherence behavior.2,55 This variable was defined using inpatient claims, 
outpatient claims, the Chronic Conditions file, and the Other Chronic Conditions CCW files 
using corresponding ICD-9- CM codes (table 9).  
 
Table 9: Cognitive impairment conditions and corresponding ICD-9-CM codes 
Condition  ICD-9-CM codes 
Dementia  290.0, 290.10, 290.11, 290.12, 290.13, 
290.20, 290.21, 290.3, 290.40,290.41, 290.42, 
290.43, 290.8, 290.9 
Schizophrenia  295.xx 
Bipolar disorder 296.0, 296.1, 296.4-296.9 
 
Number of unique medications: 
This variable was calculated by using prescription claims data in the PDE file. The 
unique medication for each beneficiary in the cohort was identified using the GNN variable 
(generic name of the drugs). The number of a unique medications was coded as a continuous 
variable indicating the number of different medications each beneficiary received in the baseline 
period. This is an important variable to consider since increased number of medications and 
polypharmacy impact medication adherence behavior.64,65 
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Anticoagulant access and INR monitoring: 
Access to an anticoagulant clinic was identified by using Healthcare Common Procedure 
Coding System codes 85610 or 85730, which represent claims submitted for INR testing or the 
prothrombin test. This variable was coded as a continuous variable indicating number of 
anticoagulant clinic access or the INR monitoring throughout the index period (12 months after 
initiating warfarin therapy). 
However, after analyzing the data, we found that almost two thirds of the study 
population (68.7%) had missing values for the “anticoagulant clinic access” variable. This is a 
limitation of the data source. The data used in this study only capture hospital outpatient claims. 
Thus, there was not sufficient information regarding access to an anticoagulant clinic for a large 
proportion of the study population. As a consequence, the number of INR monitoring for this 
variable could not be determined accurately. In other words, we were unable to capture access to 
anticoagulant clinic outside hospitals or clinics (i.e., a private clinic). To overcome this 
limitation, an indicator variable was created (0= missing value, 1= a value in the “number 
anticoagulant access” variable).  The indicator variable was included in all the study models, and 
if the significance of the indicator variable was not statistically significant, this was interpreted 
as an indication that the missing values in the “anticoagulant clinic access” variable did not 
impact study outcomes.  
Medicare coverage gap variable: 
This variable was calculated using benefit phase variables from the PDE file. Medicare 
covers most drug-related costs until the beneficiary reaches a defined threshold each year. When 
the beneficiary exceeds that threshold, he/she enters into the coverage gap (i.e., “donut hole”), in 
which the Medicare no longer covers the medication expense. The coverage gap variable was 
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coded as a dummy variable indicting whether or not the beneficiary was in the coverage gap 
during the baseline period. This variable has also been found to impact patient’s medication 
adherence behavior.66  
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3.1 Specific Aim 1 
Specific Aim 1A Identify and describe the trajectory groups of warfarin adherence in 
patients with AF in a Medicare population 
 
Specific Aim 1B: Estimate the likelihood of patients belonging to each adherence 
trajectory 
 
Specific Aim 1C: Identify characteristics of trajectory members and factors associated with 
each adherence trajectory 
 
Outcome measures: 
The primary outcome measure was the trajectories of warfarin adherence over the time 
period. The Group Based Trajectory Model (GBTM) was used to identify different group 
patterns of adherence to warfarin in the study population over a one-year study period and to 
estimate likelihood of patients belonging to each adherence trajectory. 
Adherence measures: 
First, we assessed adherence by creating a supply diary for each patient in the cohort, 
indicating if the warfarin was available on each day for 12 months after the index date (first 
prescription of warfarin). The supply diary was created by linking all warfarin-related pharmacy 
claims based on days’ supply and dispensing date variables in the PDE file.  Then, the monthly 
proportion of days covered (PDC) was calculated for each patient in the cohort for a period of 12 
months after the index date. Monthly PDC was calculated by dividing number of days “covered” 
for warfarin in a given month by 30 days: 
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Monthly Proportion Days Covered (PDC)=	"#$%&'	()	*+,-	“/(0&'&*”		2&'	$(34567	*+,-   
Each patient in the cohort would have 12 calculated PDC values for one year after initiating 
warfarin therapy. The PDC was adjusted when the next prescription was filled before the end of 
supply of the previous fill. For example, figure 3 shows the case in which the second claim, filled 
on Oct. 10, 2008, occurs before the end of supply of the first claim (Sept.15, 2008). In this case, 
the PDC was calculated by adjusting the overlapping days’ supply and shifting the fill date of the 
second claim forward until the end of supply of the first claim (i.e., the new fill date of the 
second claim, thus becomes Oct.15, 2008).67  
	
Figure 3: Example of adjusted PDC for overlapping days’ supply 
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Group based trajectory model: 
The 12 monthly measures for warfarin adherence for each patient in the cohort were 
modeled using GBTM. Each patient was classified into a trajectory group based on his/her 
adherence pattern over the one-year period. When running the trajectory model, several multiple 
regression models were estimated simultaneously, where the outcome was the probability of 
being adherent (monthly PDC) and the independent variable was time in months. 
The GBTM is an application of finite mixture models and the estimation of model parameters is 
a product of the maximum likelihood function. These parameters determine the shape of the 
trajectories and the size of the groups. The GBTM estimates the posterior probabilities or the 
membership probabilities for each beneficiary in the cohort, which in turn determine the 
assignment of the beneficiaries to the trajectory groups according to the highest membership 
probability.32 
The PROC TRAJ function of SAS 9.4® was used in this study to run the GBTM. The PROC 
TRAJ procedure is not part of the base SAS software, and was downloaded separately from B. 
Jones’s website.68  
The main inputs necessary to run the GBTM are: 
1. Outcome variable: the 12 repeated measures of PDC for each patient in the cohort. 
2. Independent variable: the 12 time variables (month1-month12), which patient’s 
adherence were measured over. 
3. Distribution of the outcome variable: as the PDC is proportion data (censored data), so 
the distribution was specified as censored normal distribution. 
4. Number of groups. 
5. Order of each equation that describes change over time for each group. 
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 The model fitting process of the GBTM is iterative and required running the model 
several times, changing the number of groups and assigned order each time, in order to achieve 
the best fitted model for the data. The model fit process can be summarized in the following 
steps: 
1. Determining the maximum number of groups. 
2. Select the appropriate order for each group and run models, starting with one group 
model until maximum assigned number of groups is reached in a stepwise manner. 
3. Select the the model with the appropriate number of groups that best fits the data. 
 In step one, the maximum number of groups can be determined based on the literature. 
In this study, the maximum number of groups was limited to six groups for simplicity of 
interpretations and to avoid small size of trajectory groups.44,69 
 In the second step, the shape of the trajectory for each group over time was determined 
based on the proper order of each equation. According to the recommendation by Nagin et al., 
each group should be assigned to second order (quadratic order) at the beginning of the analysis 
and then changing it until reaching an appropriate order for the best model. The PROC TRAJ 
function can model up to a fourth order polynomial.  As a general rule, one group model with 
quadratic order is tested first. If the parameters of the single quadratic model are not significant, 
then another model is run by changing the order of the group from quadratic to linear or cubic 
until getting significant parameters. If the parameters of the single quadratic model are 
significant, then a two groups quadratic model is performed. This process is repeated with 
additional number of the trajectory groups until the six groups model (i.e., maximum number of 
groups). In this study, the parameters of the quadratic order for all six models were significant so 
there was no need to change the order of the groups to linear, cubic, or quartic. 
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       After performing the second step, six models were produced with different number of 
groups and shapes of trajectories. The selection of the final model is based on three main criteria: 
1) Bayesian information criteria (BIC); 2) the proportion of beneficiaries in each group is not 
less than 5% of total sample; and 3) Nagin’s criteria.  
The BIC values are estimated for each model and considered the fit index when comparing 
between models. To compare between competing models, the log Bayes factor was used and is 
calculated by subtracting the BIC of the simple model (model with fewest groups) from each 
successive, more complex model (model with more groups) and multiplying it by two:70,71  
2∆BIC = 2 x [ BIC (complex) – BIC (simple)] 
      The interpretation of the log Bayes factor in terms of model fit is explained according to 
guidelines by Jones et al., (table 10) 
Table 10: Interpretation of logged Bayes factor (2*∆BIC) for model selection 
2*∆BIC Evidence against Ho 
0 to 2 Not worth mentioning 
2 to 6 Positive 
6 to 10 Strong 
> 10 Very strong 
 
       According to this guideline, a logged Bayes factor value of 0 to 2, for example, indicates 
weak evidence that a more complex model has a better fit compared to the simple model. While 
a value of more than ten is interpreted as very strong evidence of better fit of the complex model.   
First, the model with two trajectory groups is compared to the single group model by calculating 
log Bayes factor. If the value is indicative of a better fit (i.e., 2*∆BIC > 2), then the two groups 
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model is compared to three groups model. This process is continued, by comparing to each the 
increasingly complex model, until there is no more evidence for improvement in the model fit.  
       Once the number of trajectory groups was determined, the beneficiaries were classified into 
the groups based on the highest posterior probability (maximum-probability assignment rule).27,34 
An example for applying the maximum-probability assignment rule to assigned beneficiaries to 
groups is shown in table 11. This process is done automatically by the PROC TRAJ function in 
SAS. 
Table 11: Example of assigning beneficiaries to trajectory groups based on the maximum-
probability assignment rule 
Beneficiary ID Probability 
to group 1 
Probability 
to group 2 
Probability 
to group 3 
Probability 
to group 4 
Assigned 
group 
1 0.21 0.63 0.02 0.14 2 
2 0.24 0.02 0.07 0.67 4 
3 0.54 0.11 0.33 0.02 1 
 
      After selecting the appropriate number of groups according the logged Bayes factor, the 
proportion of the beneficiaries in each group is evaluated. Ideally, the proportion of beneficiaries 
in each group should not be less than 5% of the total sample. 
      The third criteria for model selection is Nagin’s criteria for model adequacy which indicates 
how well or precisely the beneficiaries are assigned to each trajectory group based on average 
posterior probability.27,44 The average posterior probability is an indicator of the internal 
reliability of the model. It is calculated for each group and equals the average assigned posterior 
probabilities of the beneficiaries to trajectory using the maximum-probability assignment rule. 
An average posterior probability greater of 0.7 for all the groups is recommended. 
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            The major outputs for the trajectory model are the appropriate trajectory groups of 
warfarin adherence, the membership probability for each beneficiary in each group, and 
graphical illustration of trajectory curves, with PDC values on the y-axis and time (months) on 
the x-axis.  
Statistical analysis: 
Baseline characteristics of the cohort, stratified by trajectory group, were described, with 
means and standard deviation calculated for continuous variables and percentages for categorical 
variables.  
To describe associations between patients’ characteristics, including confounders in the 
conceptual framework, and trajectory groups, a multinomial regression model was used: 
Log (9(;<=>?@) 9(BCD	;<=>? ∗)) = β0 + β1 AGE + β2 GENDER + β3 RACE + β4 LIS +                     
β5 COVERAGE_GAP + β6 CHADS2-VASc + β7 CCI +β8 DEPRESSION+β9 
COGNITIVE_IMPAIRMENT+ β10 NO_MEDICATION+ β11 INR_MONITORING 
*Ref group: perfectly adherent 
            The outcome of interest was the odds of being in a given group compared to a perfectly 
adherent group. Odds ratios and 95% Confidence intervals (95% CI) from the multinomial 
regression model were reported. All statistical analyses were conducted using SAS 9.4® and a 
significance level of α ≤ 0.05 was assigned. 
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3.2 Specific Aim 2 
Specific Aim 2A: Estimate the rates of hospitalizations related to a stroke or bleeding event 
(clinical outcomes) associated with each adherence trajectory 
 
Specific Aim 2B: Evaluate the association between warfarin adherence trajectory group 
membership and the likelihood of hospitalization due to a stroke or bleeding event 
Outcome measures: 
 For Specific Aim 2, the outcome of interest is time to first hospitalization related to AF 
or warfarin therapy. In this study, a hospitalization event is defined as the first admission due to a 
bleeding event or stroke in the follow-up period (one year after first warfarin fill). The follow-up 
was restricted to only one year to limit the assessment to hospitalization events occurring at the 
same time as the observed adherence patterns. The hospitalization events were identified from 
the corresponding ICD-9-CM codes as the primary discharge diagnosis for hospitalization or 
admitting diagnosis in the inpatient file. The defined ICD-9 codes are listed in table 12. 
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Table 12: ICD-9 codes and corresponding definitions for hospitalization events 
Condition  ICD-9 codes 
Major Bleeding 
Gastrointestinal bleeding  456.0, 456.20, 530.21, 530.7, 530.82, 531.0x, 
531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 
532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 
534.2x, 534.4x, 534.6x, 535.01, 535.11, 535.21, 
535.31, 535.41, 535.51, 535.61, 535.71, 537.83, 
537.84, 562.02, 562.03, 562.12, 562.13, 568.81, 
569.3, 569.85, 578.x  
Non-traumatic intracranial 
hemorrhage   
430, 431, 432.x  
Traumatic intracranial hemorrhage   852.x, 853.x  
Bleeding from other sites 423.0, 459.0, 596.7, 599.71, 719.1x, 784.8, 786.3  
Stroke 
Ischemic stroke 433.x1, 434.x1, or 436  
Transit ischemic attack (TIA) 435.X  
Systemic embolism 444.x  
 
Statistical analysis: 
 Baseline characteristics of the cohort were described between patients who experienced 
hospitalization events in the follow-up period and those that did not have an event, with means 
and standard deviation for continuous variables and percentages for categorical variables. In 
order to examine the association between trajectory groups and the first hospitalization event, 
while controlling for potential confounders, a multivariable Cox proportional hazards model was 
used:  
Log [h(t|x)] = β0 + β1 TRAJ* + βX X** 
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[h(t|x)]: hazard ratio of hospitalization 
*TRAJ: Warfarin adherence trajectory groups  
**X: Confounders 
 The dependent variable in the model is time to first hospitalization event due to bleeding 
or stroke events in the follow-up period. Time units were coded as days starting after one year 
from the index date. Beneficiaries were followed until the first hospitalization event, death, or 
end of follow-up period. Cases were coded as censored if the hospitalization event had not 
occurred by the end of the follow up period, or if the beneficiary died. The proportion of patients 
who experienced events was presented by trajectory group.  Results for the association between 
adherence trajectories and time to first hospitalization were reported as a hazard ratio (HR) and 
95% CI. Statistical significance was defined as  α ≤ 0.05. 
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3.3 Specific Aim 3 
Specific Aim 3A: Estimate the AF-related costs for each adherence trajectory group 
 
 Outcome measures: 
The primary outcome for this aim was AF-related costs associated with each trajectory 
adherence group through the follow-up period. In this study, the costs included were direct 
medical costs from the societal perspective. The direct medical costs associated with AF were 
calculated by including cost of 1) anticoagulant clinic services, 2) outpatient visits, and 3) 
inpatient visits related to bleeding or thromboembolic events. Use of anticoagulant clinic 
services was identified using corresponding CPT codes for INR testing (CPT codes 
'85610','85730').  AF-related inpatient and outpatient visits were identified using corresponding 
ICD-9-CM codes for AF, bleeding or thromboembolic events in the principal diagnosis, 
admitting diagnosis or the first three diagnosis variables in the inpatient and outpatient Medicare 
files (Table 8).  Total cost was computed by summing the amount paid by Medicare, the 
beneficiary and other third-party payers, if any. The amount paid by Medicare, other third party 
payers, and beneficiary were obtained from the base inpatient and outpatient files, but the 
amount paid by the beneficiary for anticoagulant clinic was identified from the Revenue Center 
files and were linked to the base file by a unique claim identifier (CLM_ID). The different cost 
components were calculated as follows:  FCGHIJ<C KhJ<C = @L=>MN ?JHG OP FCGHIJ<C + (QHCL JL=>MN ?JHG  R>LOC< =D GJPK HM ISJHL)  TCMeDHIHJ<P KhJ<C = QCG>INHOSC + U=HMK><JMIC + TS==G GCG>ItHOSC V=NJS amount paid = FCGHIJ<C KhJ<C + TCMeDHIHJ<P KhJ<C + VhH<G ?J<NP ?JPLCMN 
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All costs associated with emergency department visits (ED) were already captured in the 
inpatient or outpatient billing depending if the beneficiary was admitted (inpatient) or discharged 
(outpatient) after their ED visit.  
All positive cost data were presented in $US and inflated to 2018 currency values by using the 
US Healthcare inflation rate from the Bureau of Labor Statistics (Appendix B).72 
Statistical analysis: 
            Direct medical costs associated with each adherence trajectory were calculated. Cost 
components included in the analysis were costs related to inpatient visits, outpatient visits, and 
INR monitoring. The mean of total costs related to AF associated with each trajectory group 
were reported in addition to a breakdown of cost components stratified by adherence trajectory. 
An ANOVA analysis was performed to test for differences in total cost and cost components 
(inpatient visits, outpatient visits, and INR monitoring) between different trajectory groups. All 
analyses were performed using SAS 9.4 software. A P-values less than 0.05 denoted statistical 
significance. 
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3.4 Sensitivity Analysis 
 To confirm robustness of the study results, two sensitivity analyses were conducted. As 
medication adherence can have an impact on short-term clinical outcomes, a three months’ 
follow-up period was examined in place of the one-year follow-up period used in the main 
analysis. Another sensitivity analysis was performed defining hospitalization events due to stroke 
or bleeding using corresponding ICD-9 codes in the secondary discharge diagnosis field instead 
of the primary diagnosis field.    
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Chapter 4: Results 
In this section the final study population is described. This is followed by the description 
of the results for each individual aim.  
4.1 Study Population 
From the random sample of Medicare beneficiaries, 50,636 beneficiaries met the 
eligibility criteria, i.e., AF patients, age ≥65, with three years of continuous enrollment in 
Medicare Part A, B and D. Of those, 3,246 beneficiaries were identified as new users of warfarin 
with at least two prescriptions and were identified to be the population of interest (Figure 4). On 
average beneficiaries were 78 years old, 63% women, and 91% white (Table 13).  
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Total Medicare beneficiaries in 2008 
 (2,631,893) 
Include FFS beneficiaries, age ≥65 years old 
with full coverage of Medicare part A, B, and D (n=650,399) 
 
Beneficiaries with at least one inpatient or two outpatient 
claims for AF in the baseline period (n= 63,870) 
Included Beneficiaries (n=50,636) 
Exclude beneficiaries with: 
• Prior diagnosis of metastatic cancer 
• Palliative care  
• Not continuously enrolled in 
Medicare 
Final population (n=3,246) 
Exclude beneficiaries who had: 
• Warfarin claim in the baseline period 
(prevalent users) 
• With less than two prescriptions of 
warfarin 
Figure 4: Eligibility flow chart for the study cohort 
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Table 13: Baseline characteristics for the study cohort 
Characteristics Total  
(3,246) 
Age   
     Mean (SD) 78.42 (7.02) 
Gender (%)  
     Male 37.34    
     Female  62.66  
Race (%)  
     White 91.74  
     Black 3.82 
     Others  4.44  
LIS eligibility (%)  
     No  72.64  
     Yes  27.36  
CCI  
     Mean (SD) 3.06 (2.28) 
     Median   (min-max) 3.00 (0-13) 
CHADS2-VASc score  
     Mean (SD) 5.10 (1.74) 
     Median (min-max) 5.00 (1-9) 
Depression (%)  
     No 80.62  
     Yes  19.38  
*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility, CCI: Charlson Comorbidity 
Index 
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Table 13: Continued 
 
Characteristics Total  
(3,246) 
Cognitive impairment and mental disorders (%)  
     No  91.25  
     Yes  8.75  
Number of chronic medications   
     Mean (SD) 13.41 (6.15) 
     Median (min-max) 12.50 (1-39) 
Coverage Gap  
     Yes 40.70  
     No 59.30  
Anticoagulant access (%)  
     Yes 32.10  
     No 67.90  
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4.2 Specific Aim 1 
Specific Aim 1A: Describe the trajectory groups of warfarin adherence in patients with AF 
in Medicare population 
Specific Aim 1B: Estimate the likelihood of patients belonging to each adherence 
trajectory 
Six trajectory models were performed ranging from one group to six groups (figure 5). As the 
number of groups increased, there was an improvement in the statistical fit (i.e., the absolute BIC 
value getting lower indicating better fit). The Bayes factor and estimated group proportions were 
used to determine the best GBTM model (Table 14). The six groups model provided the best 
statistical fit based on the Bayes factor, and the estimated proportion of the beneficiaries in each 
group were more than 5% of the total study population. Thus, the six groups model was selected 
as the final model. The parameter estimates of the final model were all significant and are 
presented in Table 15.  
Additionally, Nagin’s criteria for assessing the final model adequacy in assigning the 
beneficiaries in each trajectory group was checked, and indicated that the six group model 
performed well in distinguishing between beneficiaries with different adherence patterns  (i.e., 
average posterior probability for each trajectory group is ≥ 0.7) (Table 16).  
Figure 6 illustrates six distinct adherence patterns for warfarin during the first year after 
initiating treatment. The six adherence trajectories were described and labeled based on the 
timing of discontinuation of warfarin and the level of the PDC: 1) Rapid decline non-adherence 
group (11.5%, mean PDC: 0.22), 2) moderate non-adherence group (24%, mean PDC: 0.56), 3) 
rapid decline then increasing adherence group (6.8%, mean PDC: 0.85), 4) moderate decline 
non-adherence group (8.2%, mean PDC: 0.51), 5) slow decline non-adherence group (24.3%, 
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mean PDC: 0.84), and 6) perfect adherence group (25.3%, mean PDC: 0.99) (table 16).  Table 17 
shows the baseline characteristics of beneficiaries stratified by trajectory groups.  Relative to 
other adherence groups, the beneficiaries in the “rapid decline then increase adherence group” 
were more likely to be male. Overall, beneficiaries in the “perfect adherence group” were more 
likely to be eligible for the LIS program and to suffer from mental health conditions. 
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Figure 5: Trajectory models using one to six groups. In each plot, the solid lines represent the predicted probability of adherence in 
each group, and the dotted lines represent the observed proportion. The proportion of beneficiaries in each group is given under each 
graph 
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Table 14: Bayesian Information Criterion (BIC) values and percentage of patient in each group for the six models 
Model BIC Bayes 
factor 
                            Percentage of patients in each group   
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
1 group  -37,135.97 - 100% - - - - - 
2 groups -30,902.02 12,467.9 45.37% 54.63% - - - - 
3 groups -28,608.53 4,586.98 16.42% 46.80% 36.78% - - - 
4 groups -27,667.02 1,883.02 12.90% 8.77% 41.20% 37.13% - - 
5 groups -27,139.29 1,055.46 11.89% 8.50% 27.39% 27.88% 24.34% - 
6 groups -26,778.85 720.88 11.53% 23.95% 6.79% 8.17% 24.28% 25.27% 
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Table 15: Parameter estimates of adherence trajectories for the six-groups model 
Trajectory group Parameter order Estimate P-value 
1. Rapid decline non-adherence 
group 
Intercept 2.59 <0.001 
 Linear -0.87 <0.001 
 Quadratic 0.04 <0.001 
2. Moderate non-adherence group Intercept 1.40 <0.001 
 Linear -0.28 <0.001 
 Quadratic 0.02 <0.001 
3. Rapid decline then increasing 
adherence group 
Intercept 1.93 <0.001 
 Linear -0.58 <0.001 
 Quadratic 0.07 <0.001 
4. Moderate decline non-
adherence group 
Intercept 1.46 <0.001 
 Linear 0.18 <0.001 
 Quadratic -0.05 <0.001 
5. Slow decline non-adherence 
group 
Intercept 1.80 <0.001 
 Linear -0.12 <0.001 
 Quadratic 0.01 0.009 
6. Perfect adherence group Intercept 1.64 <0.001 
 Linear 0.20 <0.001 
 Quadratic -0.01 <0.001 
 
 
 
		 71	
 
Table 16: Model fit statistics for the six-groups model 
Trajectory group             Group size                 PDC Average Posterior 
probability* 
N % Mean  SD Mean  SD 
1. Rapid decline group 378 11.53% 0.22 0.08 0.97 0.09 
2. Moderate non-adherence group 787 23.95% 0.56 0.14 0.91 0.14 
3. Rapid decline then increasing 
adherence group 
216 6.79% 0.85 0.09 0.87 0.16 
4. Moderate decline group 262 8.17% 0.51 0.10 0.94 0.11 
5. Slow decline group 760 24.28% 0.84 0.07 0.89 0.14 
6.Perfect adherent group 843 25.27% 0.99 0.02 0.94 0.13 
*Average posterior probability: represents how well beneficiaries are classified into trajectory groups. An average posterior 
probability greater than 0.7 indicates a good model fit 
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Figure 6:Warfarin adherence trajectories in the 12 months following initiation (Final model) 
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Table 17: Baseline characteristics of study population stratified by adherence trajectory groups 
*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility 
 
 
 
 
 
 
 
 
 
Characteristics 1. Rapid 
decline 
group (n= 
378) 
2. Moderate 
non-
adherence 
group 
(n=787) 
3. Rapid 
decline then 
increasing 
adherence 
group  
(n=216) 
4. Moderate 
decline 
group  
(n=262  ) 
5. Slow 
decline group  
(n=760) 
6. perfect 
adherence 
group  
(n=843) 
Total  
(3,246) 
Age         
     Mean (SD) 78.13 (7.10) 78.02 (6.57) 78.90 (7.24) 78.13 (7.35) 78.31 (6.90) 79.01 (7.32) 78.42 (7.02) 
Gender (%)        
     Male 38.10  37.23  43.98  37.40  39.61  33.33  37.34    
     Female  61.90  62.77  56.02  62.60  60.39  66.67  62.66  
Race (%)        
     White 90.48  93.14  93.98  89.69  91.18  91.58  91.74  
     Black 3.44  3.81  2.78  3.05  4.61  3.80  3.82 
     Others  6.08  3.05  3.24  7.25  4.21  4.63  4.44  
LIS eligibility 
(%) 
       
     No  74.60  77.51  73.61  73.28  73.68  65.84  72.64  
     Yes  25.40  22.49  26.39  26.72  26.32  34.16  27.36  
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Table 17: Continued 
 
Characteristics 1. Rapid 
decline 
group (n= 
378) 
2. Moderate 
non-
adherence 
group 
(n=787) 
3. Rapid 
decline then 
increasing 
adherence 
group  
(n=216) 
4. Moderate 
decline 
group  
(n=262  ) 
5. Slow 
decline 
group  
(n=760) 
6. perfect 
adherence 
group  
(n=843) 
Total  
(3,246) 
CCI        
     Mean (SD) 3.23 (2.19) 3.07 (2.32) 2.93 (2.23) 3.14 (2.33) 3.00 (2.32) 3.03 (2.26) 3.06 (2.28) 
     Median   
(min-max) 
3.00 (0-10) 3.00 (0-12) 3.00 (0-10) 3.00 (0-11) 3.00 (0-13) 3.00 (0-11) 3.00 (0-13) 
CHADS2-
VASc score 
       
     Mean (SD) 5.04 (1.70) 5.11 (1.69) 4.98 (1.71) 4.95 (1.72) 5.06 (1.79) 5.23 (1.79) 5.10 (1.74) 
     Median 
(min-max) 
5.00 (2-9) 5.00 (1-9) 5.00 (1-9) 5.00 (1-9) 5.00 (1-9) 5.00 (1-9) 5.00 (1-9) 
Depression 
(%) 
       
     No 80.69  82.97  80.09  77.10  81.97  78.41  80.62  
     Yes  19.31  17.03  19.91  22.90  18.03  21.59  19.38  
*Abbreviation used: CCI: Charlson Comorbidity Index 
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Table 17: Continued 
 
Characteristics 1. Rapid 
decline group 
(n= 378) 
2. Moderate 
non-
adherence 
group 
(n=787) 
3. Rapid 
decline then 
increasing 
adherence 
group  
(n=216) 
4. Moderate 
decline 
group  
(n=262  ) 
5. Slow 
decline group  
(n=760) 
6. perfect 
adherence 
group  
(n=843) 
Total  
(3,246) 
Cognitive 
impairment 
(%) 
       
     No  91.27  94.28  91.67  90.08  92.24  87.78  91.25  
     Yes  8.73  5.72  8.33  9.92  7.76  12.22  8.75  
Number of 
chronic 
medications  
       
     Mean (SD) 13.68 (6.00) 13.27 (6.20) 12.69 (5.62) 13.90 (6.22) 13.11 (5.97) 13.70 (6.43) 13.41 (6.15) 
     Median 
(min-max) 
13.00 (3-37) 13.00 (1-39) 12.00 (3-32) 13.00 (2-34) 12.00 (3-37) 13.00 (2-39) 12.50 (1-39) 
Coverage Gap        
     Yes 39.95  39.26  41.20  41.22  41.97  40.93  40.70  
     No 60.05  60.74  58.80  58.78  58.03  59.07  59.30  
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Table 17: Continued 
 
Characteristics 1. Rapid 
decline group 
(n= 378) 
2. Moderate 
non-
adherence 
group 
(n=787) 
3. Rapid 
decline then 
increasing 
adherence 
group  
(n=216) 
4. Moderate 
decline 
group  
(n=262  ) 
5. Slow 
decline group  
(n=760) 
6. perfect 
adherence 
group  
(n=843) 
Total  
(3,246) 
Anticoagulant 
access (%) 
       
     Yes 32.28  34.56  29.17  28.63  31.58  32.03  32.10  
     No 67.72 65.44  70.83  71.37  68.42  67.97  67.90  
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Specific Aim 1C: Identify patients’ characteristics and factors associated with each adherence 
trajectory 
The results of the multinomial logistic regression model for identifying predictors of 
adherence trajectory groups are presented in Table 18. No significant differences were found 
between adherence trajectories and demographic characteristics, presence of clinical depression, 
number of chronic medications, or access to an anticoagulant clinic. However, Hispanic, Asian, 
or North American natives together had twice the odds of being in the “moderate decline” group 
compared to the “perfect adherence” group (others vs. white OR: 2.01, 95% CI: 1.11-3.63). LIS 
eligibility was found to be a significant predictor of adherence trajectory groups. Specifically, 
being eligible for the LIS program was associated with higher odds of being in “perfect 
adherence” group compared to other groups. Having more cognitive conditions was associated 
with lower risk for being in the “moderate non-adherent” and “slow decline” groups relative to 
the “perfect adherence” group (OR: 0.51, 95%CI: 0.35-0.74, OR: 0.68 95%CI: 0.48-0.97, 
respectively). Keeping other covariates constant, with every unit increase in the CCI there were 
increased odds of being in the “rapid decline” and “moderate decline” group” relative to the 
“perfect adherent” group (OR:1.12, 95%CI: 1.04-1.2, OR: 1.11, 95%CI: 1.02-1.2, respectively).  
Moreover, with every unit increase in the stroke risk score (CHADS2-VASc score), there was a 
15% decrease in the odds of being in “moderate decline” group compared to being in the “perfect 
adherence” group (OR: 0.85, 95% CI: 0.76-0.96). The odds for being in the “slow decline” group 
compared to the “perfect adherence” group were 29% higher for beneficiaries who had been in 
the insurance gap (OR: 1.29, 95% CI: 1.02-1.63).  
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Table 18: Multinomial Logistic Regression: Predictors of Adherence Trajectory Group 
 *Abbreviation used: LIS eligibility: Low Income Subsidy eligibility, CCI: Charlson Comorbidity Index 
Characteristics 1. Rapid 
decline group, 
OR (95%CI) 
2. Moderate 
non-adherence  
group, OR 
(95%CI) 
3. Rapid 
decline then 
increasing 
adherence 
group, OR 
(95%CI) 
4. Moderate 
decline group, 
OR (95%CI) 
5. Slow decline 
group, OR 
(95%CI) 
6. perfect 
adherence 
group  
(Ref) 
Age  0.99 (0.97-1.01) 0.98 (0.96-1.00) 1.01 (0.98-1.03) 1.00          
(0.97-1.02) 
0.99 (0.98-1.01) 1 
Gender       
     Male Ref Ref Ref Ref Ref Ref 
     Female  1.03 (0.77-1.38) 0.98 (0.78-1.24) 0.70 (0.49-1.00) 1.09 (0.78-
1.52) 
0.86 (0.68-1.09) 1 
Race        
     White Ref Ref Ref Ref Ref Ref 
     Black 1.11 (0.56-2.19) 1.52 (0.74-2.12) 0.98 (0.36-2.21) 1.01 (0.45-
2.29) 
1.50 (0.90-2.49) 1 
     Others  1.70 (0.98-2.95) 0.84 (0.49-1.43) 0.73 (0.33-1.77) 2.01 (1.11-
3.63) 
1.07 (0.65-1.76) 1 
LIS eligibility 0.60 (0.44-0.82) 0.58 (0.45-0.73) 0.79 (0.54-1.14) 0.62 (0.44-
0.88) 
0.69 (0.54-0.88) 1 
CCI 1.12 (1.04-1.2) 1.05 (0.99-1.11) 1.04(0.95-1.14) 1.11 (1.02-1.2) 1.03 (0.97-1.10) 1 
CHADS2-VASc 
score 
0.91 (0.82-1.01) 1.01 (0.93-1.10) 0.96 (0.84-1.09) 0.85 (0.76-
0.96) 
0.99 (0.90-1.07) 1 
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Table 18: Continued  
Characteristics 1. Rapid 
decline group, 
OR (95%CI) 
2. Moderate 
non-adherence  
group, OR 
(95%CI) 
3. Rapid 
decline then 
increasing 
adherence 
group, OR 
(95%CI) 
4. Moderate 
decline group, 
OR (95%CI) 
5. Slow decline 
group, OR 
(95%CI) 
6. perfect 
adherence 
group  
(Ref) 
Depression  0.91 (0.66-1.26) 0.83 (0.64-1.08) 1.11 (0.75-1.65) 1.13 (0.80-
1.62) 
0.91 (0.70-1.81) 1 
History of 
cognitive 
impairment and 
mental disorders 
0.79 (0.51-1.21) 0.51 (0.35-0.74) 0.70 (0.40-1.22) 0.90 (0.56-
1.46) 
0.68 (0.48-0.97) 1 
Number of chronic 
medications 
1.00 (0.97-1.03) 0.99 (0.97-1.01) 0.97 (0.94-1.00) 1.01 (0.98-
1.03) 
0.98 (0.96-1.00) 1 
History of being in 
the insurance gap  
1.03 (0.77-1.37) 1.10 (0.87-1.39) 1.38 (0.97-1.97) 1.05 (0.75-
1.46) 
1.29 (1.02-1.63) 1 
Having access to 
anticoagulant 
clinic 
0.95 (0.73-1.25) 1.11 (0.89-1.38) 0.88 (0.62-1.23) 0.81 (0.59-
1.11) 
0.97 (0.78-1.21) 1 
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4.3 Specific Aim 2 
Specific Aim 2A: Estimate the rates of hospitalizations related to a stroke or bleeding event 
(clinical outcomes) associated with each adherence trajectory 
 
     Overall, 7.5% of the sample population had an AF-related hospitalization event (figure 7). As 
shown in table 19, beneficiaries who had AF-related hospitalization had slightly lower overall 
PDC (PDC for hospitalized: 0.68, non-hospitalized: 0.71). The AF-related hospitalization events 
in the 12-month period following therapy initiation was least frequent in the “rapid decline then 
increasing adherence”, “slow decline”, and “perfect adherent” groups (6.02%, 6.18%, and 
7.35%, respectively) and highest in the “moderate decline” and “rapid decline” groups (9.54%, 
and 8.73%, respectively). 
	
Figure 7: Percentage of AF-related hospitalization after one year of initiating warfarin therapy 
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Table 19: Baseline characteristics for hospitalized compared to non-hospitalized patients 
*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility 
Characteristics Hospitalized 
 (7.46%) 
Non-hospitalized 
(92.54% ) 
Adherence trajectories (%)   
1. Rapid decline group 8.73% 91.27% 
2. Moderate non-adherence group 7.88% 92.12% 
3. Rapid decline then increasing adherence group 6.02% 93.98% 
4. Moderate decline group 9.54% 90.46% 
5. Slow decline group 6.18% 93.82% 
6.Perfect adherent group 7.35% 92.65% 
Overall PDC 0.68 0.71 
Age    
     Mean (SD) 78.95% (7.02) 78.38 (7.02) 
Gender (%)   
     Male 5.36% 94.64% 
     Female  8.70% 91.30% 
Race (%)   
     White 7.32% 92.68% 
     Black 7.26% 92.74% 
     Others  10.42% 89.58% 
LIS eligibility (%)   
     No  6.70% 93.30% 
     Yes  9.46% 90.54% 
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Table 19: Continued 
Characteristics Hospitalized 
 (7.46%) 
Non-hospitalized 
(92.54% ) 
CCI   
     Mean (SD) 4.04 (2.30) 2.98 (2.26) 
     Median   (min-max) 4.00 (0.00-11.00) 3.00 (0.00-13.00) 
CHADS2-VASc score   
     Mean (SD) 5.83 (1.67) 5.04  (1.74) 
     Median (min-max) 6.00 (2.00-9.00) 5.00 (1.00-9.00) 
Depression (%)   
     No 7.11% 92.89% 
     Yes  8.90% 91.10% 
Cognitive impairment and mental 
disorders (%) 
  
     No  7.53% 92.47% 
     Yes  6.69% 93.31% 
Number of chronic medications    
     Mean (SD) 14.50 (6.45) 13.32 (6.12) 
     Median (min-max) 13.00 (2.00-34.00) 12.00 (1.00-39.00) 
Coverage Gap   
     Yes 7.34% 92.66% 
     No 7.53% 92.47% 
Anticoagulant access (%)   
     Yes 7.77% 92.23% 
     No 7.30% 92.70% 
*Abbreviation used: CCI: Charlson Comorbidity Index 
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Specific Aim 2B: Evaluate the association between warfarin adherence trajectory group 
membership and the likelihood of hospitalization due to a stoke or bleeding event 
 
  Results for the Cox proportional hazard model are presented in table 20. Even though no 
statistically significant differences were found in the hazard of hospitalization between the 
adherence groups, there were higher odds of hospitalization among the lower adherence groups 
(moderate adherence, moderate decline non-adherence and the rapid decline non-adherence), 
compared to perfect adherence group. Beneficiaries in the “rapid decline” and “moderate non-
adherence” groups had 23% and 34% higher odds of being hospitalized in the year after 
initiating warfarin treatment compared to the “perfect adherence” group, respectively.  
Other factors associated with an increased risk of AF-related hospitalization events were 
gender, Charlson comorbidity index, CHADS2-VASc score, and being in the Medicare coverage 
gap. In the study population, females had 41% higher risk of being hospitalized compared to 
males (P-value = 0.03). After adjustment for all covariates, with every unit increase in the 
Comorbidity Index and the stroke risk score there is a 16% and 17%, respectively, higher odds of 
being hospitalized in the year after initiating warfarin treatment (P-values <0.0001, <0.005 
respectively).  
Finally, the proportionality assumption for the Cox proportional model was evaluated by 
examining the log minus log curve and the Schoenfeld residuals. Based on the graphs and the p-
value for the Schoenfeld residuals, the proportionality assumption of the model was satisfied. 
(See Appendix C, D, and E) 
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Table 20: Multivariable Cox Proportional Hazard Models of Adherence Trajectories of warfarin 
and risk of AF-related hospitalization 
Characteristics AF-related hospitalization 
 HR (95%CI) P-value 
Trajectory group (ref= perfect adherent) REF REF 
1. Rapid decline group 1.23 (0.80-1.88) 0.35 
2. Moderate non-adherence group 1.10 (0.77-1.56) 0.62 
3. Rapid decline then increasing adherence group 0.88 (0.48-1.61) 0.68 
4. Moderate decline group 1.34 (0.84-2.14) 0.22 
5. Slow decline group 0.87 (0.59-1.27) 0.47 
Age 0.99 (0.97-1.04) 0.51 
Gender (ref= Male) 1.41 (1.03-1.94) 0.03 
Race (ref= White) REF REF 
     Black 0.65 (0.33-1.29) 0.22 
     Others  1.29 (0.75-2.23) 0.36 
LIS eligibility  1.26 (0.94-1.69) 0.13 
CCI 1.16 (1.08-1.24) <0.0001 
CHADS2-VASc score 1.17 (1.05-1.30) <0.005 
Depression  1.02 (0.75-1.40) 0.89 
Cognitive impairment and mental disorders  0.67 (0.41-1.08) 0.10 
Number or chronic medications  1.00 (0.97-1.02) 0.77 
Coverage gap 0.70 (0.52-0.95) 0.02 
AC indicator 0.86 (0.65-1.14) 0.29 
*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility, CCI: Charlson Comorbidity Index 
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4.4 Specific Aim 3 
Specific Aim 3A: Estimate the AF-related costs for each adherence trajectory group 
Table 21 presents direct AF-related health care costs for Medicare beneficiaries treated with 
warfarin during the follow-up period stratified by adherence trajectory groups. Because the cost 
data were predictably extremely right-skewed (Figure 8) and there was a large number of zero 
values (67%-83%), the cost variables were log-transformed. By taking the log, the cost data 
become more standardized and demonstrate closer to a normal distribution This transformation 
leads to more reliable estimates and the variation in the means is reduced. Table 22 presents log 
direct AF-related health care costs for Medicare beneficiaries treated with warfarin stratified by 
adherence trajectory groups.  
 Table 22 presents log direct AF-related health care costs for Medicare beneficiaries treated 
with warfarin stratified by adherence trajectory groups.  
The log of monitoring cost and outpatient cost were found to differ significantly among the 
trajectory groups (p-value<0.0001, 0.0013, respectively). Mean log monitoring costs were found 
to be highest among beneficiaries in the “perfect adherence” and “moderate non-adherence” 
groups, and lowest among the “moderate decline” group. The mean log outpatient cost was 
significantly higher among the “moderate non-adherence” group compared to other trajectory 
groups (table 22).  
Beneficiaries in the “rapid decline” group were found to have the highest inpatient costs as 
compare to the other trajectory groups, but the differences were not statistically significant (p-
value= 0.33). Similar to mean log outpatient cost, mean log total cost was higher among the 
“moderate non-adherence” group compared to other trajectory groups, but this difference was 
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not statistically significant (p-value = 0.23). Among all the trajectory groups, the majority of the 
costs were attributed to inpatient costs. 
	
Figure 8: Distribution of total AF-related direct medical cost 
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Table 21: Mean AF-related costs stratified by trajectory groups 
 
 
 
 
 
 
Variable 1. Rapid 
decline 
group,  
Mean (SD)  
2. Moderate 
non-
adherence 
group,  
Mean (SD) 
3. Rapid decline 
then increasing 
adherence 
group,  
Mean (SD) 
4. Moderate 
decline 
group,  
Mean (SD) 
5. Slow 
decline 
group, 
Mean (SD)  
6. perfect 
adherence 
group, 
Mean (SD)  
P-value 
Inpatient cost 2,756.61 
(7,480.18) 
2,686.93 
(9,069.58) 
1,676.31 
(5,637.46) 
2,400.38 
(6,907.50) 
2,239.20 
(9,511.57) 
2,555.00 
(9,987.34) 
0.6146  
Outpatient cost 181.02 
(977.28) 
349.40 
(2741.49) 
135.53  
(544.48) 
102.30 
(473.43) 
172.83 
(1,014.71) 
264.18 
(1,350.88) 
0.1509  
INR monitoring cost 7.57 
(33.81) 
19.14  
(67.79) 
14.86  
(48.63) 
4.85  
(26.24) 
19.98  
(77.77) 
20.76  
(68.44) 
0.0003  
Total cost 2,945.2 
(7,609.46) 
3,055.47 
(9,590.49) 
1,826.7 
(4,916.03) 
2,507.53 
(6,983.44) 
2,432.01 
(7,240.56) 
2,839.94 
(11,133.63) 
0.4178  
 
		 88	
Table 22: Mean log AF-related log costs stratified by trajectory groups 
 
Variable 1. Rapid 
decline 
group,  
Mean (SD)  
2. Moderate 
non-
adherence 
group,  
Mean (SD) 
3. Rapid decline 
then increasing 
adherence 
group,  
Mean (SD) 
4. Moderate 
decline 
group,  
Mean (SD) 
5. Slow 
decline 
group, 
Mean (SD)  
6. perfect 
adherence 
group, 
Mean (SD)  
P-value 
Inpatient cost 2.23 
(4.64) 
2.11 
(4.53) 
1.57 
(4.00) 
2.12 
(4.52) 
1.80 
(4.24) 
1.89 
(4.33) 
0.33 
Outpatient cost 0.96 
(2.61) 
1.44 
(3.12) 
1.19 
(2.79) 
0.74 
(2.33) 
1.09 
(2.70) 
1.40 
(3.05) 
0.0013 
INR monitoring cost 0.54 
(1.48) 
1.02 
(2.06) 
0.85 
(1.93) 
0.36 
(1.24) 
0.91 
(1.98) 
0.97 
(2.07) 
<0.0001 
Total cost 3.02 
(4.84) 
3.40 
(4.85) 
 
2.76 
(4.44) 
2.70 
(4.71) 
2.99 
(4.61) 
3.17 
(4.74) 
0.23 
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 4.5 Sensitivity analysis 
 
1. Sensitivity Analysis One: Three month follow-up period instead of one year 
In the first sensitivity analysis, the follow-up period was defined as three months instead of 
one year (as in the main analysis) to capture the short-term impact of warfarin adherence on 
health outcomes. The number of beneficiaries who had been hospitalized in the first three 
months after initiating warfarin therapy was 74 (2.3%). Similar to the main analysis, the AF-
related hospitalization events were most frequent in the “moderate decline” group (4.2%) and 
least frequent in the “rapid decline then increasing adherence” group (0.93%) (Table 23).  
The results for the Cox proportional hazards model for the three months follow up period 
were similar to the main analysis (Table 24).  There was no statistical difference in the 
hazard ratio for AF-related hospitalization among the adherence groups. Only the 
comorbidity index and the coverage gap remained significant in this sensitivity analysis. 
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Table 23: Percentage of beneficiaries who had been hospitalization among adherence trajectories 
Characteristics Hospitalized 
 (2.28%) 
Non-hospitalized 
(97.72% ) 
Adherence trajectories (%)   
1. Rapid decline group 2.12% 97.88% 
2. Moderate non-adherence group 2.16% 97.84% 
3. Rapid decline then increasing adherence group 0.93% 99.07% 
4. Moderate decline group 4.20% 95.80% 
5. Slow decline group 1.71% 98.29% 
6.Perfect adherent group 2.73% 97.27% 
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Table 24: Multivariable Cox proportional hazard models of adherence trajectories of warfarin 
and risk of AF-related hospitalization in three months follow up period 
Characteristics AF-related hospitalization 
 HR (95%CI) P-value 
Trajectory group (ref= perfect adherent) REF REF 
1. Rapid decline group 0.76 (0.34-1.70) 0.50 
2. Moderate non-adherence group 0.80 (0.43-1.52) 0.50 
3. Rapid decline then increasing adherence group 0.37 (0.09-1.55) 0.17 
4. Moderate decline group 1.56 (0.75-3.22) 0.23 
5. Slow decline group 0.64 (0.33-1.28) 0.21 
Age 0.99 (0.95-1.03) 0.57 
Gender (ref= Male) 1.10 (0.64-1.90) 0.73 
Race (ref= White) REF REF 
     Black 0.00 (0.00-.) 0.98 
     Others  1.91 (0.83- 4.38) 0.13 
LIS eligibility  1.30 (0.76-2.22) 0.35 
CCI 1.16 (1.03-1.32) 0.02 
CHADS2-VASc score 1.18 (0.98-1.43) 0.09 
Depression  0.73 (0.39-1.35) 0.31 
Cognitive impairment and mental disorders  0.69 (0.29-1.64) 0.40 
Number or chronic medications  1.01 (0.97-1.06) 0.61 
Coverage gap 0.53 (0.30-0.93) 0.03 
AC indicator 1.07 (0.65-1.76) 0.78 
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2. Sensitivity Analysis Two: Identify hospitalization events due to stroke or bleeding in all 
diagnosis variables 
In the second sensitivity analysis, the AF-related hospitalization events were identified using 
all 25 diagnosis variables.  The number of beneficiaries who had been hospitalized was 994 
beneficiaries (30.62%). The AF-related hospitalization events were most frequent in the 
“moderate non-adherence” group (32.91%) and least frequent in the “rapid decline then 
increasing adherence” group (28.24%) (Table 25).  
Similar to the main analysis, there was no statistical difference in the hazard ratio for AF-
related hospitalization among the adherence groups. The comorbidity index and the stroke 
risk index remained statistically significant in this sensitivity analysis.  (Table 26) 
Table 25: Percentage of beneficiaries who had been hospitalization among adherence trajectories 
Characteristics Hospitalized 
 (30.62%) 
Non-hospitalized 
(69.38% ) 
Adherence trajectories (%)   
1. Rapid decline group 30.69% 69.31% 
2. Moderate non-adherence group 32.91% 67.09% 
3. Rapid decline then increasing adherence group 28.24% 71.76% 
4. Moderate decline group 29.01% 70.99% 
5. Slow decline group 30.79% 69.21% 
6.Perfect adherent group 29.42% 70.58% 
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Table 26: Multivariable Cox proportional hazard model of adherence trajectories of warfarin and 
risk of AF-related hospitalization-sensitivity analysis  
Characteristics AF-related hospitalization 
 HR (95%CI) P-value 
Trajectory group (ref= perfect adherent) REF REF 
1. Rapid decline group 1.07 (0.86-1.33) 0.57 
2. Moderate non-adherence group 1.16 (0.97-1.38) 0.10 
3. Rapid decline then increasing adherence group 1.01 (0.76-1.34) 0.96 
4. Moderate decline group 0.94 (0.72-1.22) 0.63 
5. Slow decline group 1.08 (0.90-1.29) 0.43 
Age 1.01 (1.00-1.02) 0.18 
Gender (ref= Male) 1.07 (0.92-1.24) 0.36 
Race (ref= White) REF REF 
     Black 1.03 (0.77-1.38) 0.83 
     Others  0.98 (0.72-1.34) 0.90 
LIS eligibility  1.01 (0.87-1.17) 0.91 
CCI 1.25 (1.21-1.29) <0.0001 
CHADS2-VASc score 1.08 (1.03-1.14) <0.01 
Depression  1.14 (0.98-1.33) 0.10 
Cognitive impairment and mental disorders  0.95 (0.77-1.18) 0.65 
Number or chronic medications  0.99 (0.98-1.00) 0.26 
Coverage gap 1.00 (0.86-1.15) 0.94 
AC indicator 0.77 (0.67-0.88) <0.01 
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Chapter 5: Discussion 
This chapter discusses the results of the current study and addresses its strengths and limitations. 
5.1 Specific aim 1 
The current study applied the Group Based Trajectory Model (GBTM) to identify 
adherence patterns of warfarin in AF patients during the first year after initiating treatment. The 
study revealed that six trajectory groups best describe adherence patterns for warfarin therapy 
among Medicare beneficiaries with AF. Based on the timing of warfarin discontinuation, the 
identified groups are: 1) Rapid decline non-adherence group (11.5%, mean PDC: 0.22), 2) 
moderate non-adherence group (24%, mean PDC: 0.56), 3) rapid decline then increasing 
adherence group (6.8%, mean PDC: 0.85), 4) moderate decline non-adherence group (8.2%, 
mean PDC: 0.51), 5) slow decline non-adherence group (24.3%, mean PDC: 0.84), and 6) perfect 
adherence group (25.3%, mean PDC: 0.99). 
In our study, GBTM shows an advantage over traditional adherence measures (i.e., PDC). For 
example, when using an arbitrary cut-point of 80%, beneficiaries in the “6- perfect adherence” 
group, “5- slow decline non-adherence” group, and “3- rapid decline then increasing adherence” 
groups would be collapsed into one group and classified as perfectly adherent. In other words, 
traditional measures such as PDC and MPR, would not differentiate between these three groups, 
although, the beneficiaries in two groups, “5- slow decline non-adherence”, and “3- rapid decline 
then increasing adherence”, would occasionally miss filling their warfarin prescriptions. 
Moreover, this study provides some key information regarding patterns of warfarin 
adherence. First, almost one fourth of elderly AF patients remained perfectly adherent during the 
first year of warfarin treatment. On the other hand, almost 65% of new users of warfarin 
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discontinued treatment at some point in the first year, as most of the identified adherence 
trajectories show decline in their adherence behavior over time. 
By running the GBTM, we were able to identify the time when patients are likely to be 
non-adherent, thereby detecting the best timing for delivery of appropriate interventions. For 
example, by exploring warfarin adherence trajectories we can recognize a clear separation 
between the adherence trajectories in the fifth or sixth month after initiating warfarin treatment. 
This separation between the adherence groups can provide insights for healthcare providers to 
target patients with adherence interventions. For instance, based on our model, in the six months 
follow-up visit for AF patients, the healthcare providers could focus on educating patients about 
the importance of adherence to warfarin, try to address potential adherence barriers, and/or 
identify any adverse events that may have caused them to discontinue warfarin. This is especially 
true since a large proportion of AF patients are likely to show decline in their adherence to 
warfarin after approximately six months of initiating treatment.  
To our knowledge, this is the first study to utilize GBTM to identify the distinct patterns 
of warfarin adherence in an AF Medicare population. In the previously published literature, 
GBTM has been applied to classify adherence trajectories for different medications including 
statins, oral hypoglycemic, antipsychotics, antihypertensive, and glaucoma medications. 
Consistent with this literature, the current study showed that six trajectory groups best describe 
longitudinal adherence patterns.32,44,45,48 The proportions of patients presented in our adherent 
groups were similar to those of previous studies, in which most of the population was classified 
in the “perfect adherence” group. However, Librero et. al, found that higher proportion of 
patients (almost 60%) fell in the perfect adherent group than our study. This discrepancy could 
be related to differences in the study population.69 Specifically, Librero et.al, studied the 
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adherence trajectories for patients with Coronary Heart Disease (CHD) and included both the 
incident and prevalent medication users, while in our study we only included incident users of 
warfarin. Based on the literature, incident users are likely to be poorly adherent to their 
medications compared to established patients.73,74  
Compared to previous studies, there are some similarities in the identified patterns of 
medication adherence. For example, “rapid decline non-adherence”, “moderate decline non-
adherence”, and “perfect adherence” patterns were also identified in the previous 
studies.32,34,44,47,48 In contrast, there were some differences in the intermediate trajectory groups. 
Only Lo-Ciganic et. al, and Modi et. al, have identified similar trajectories of “moderate non-
adherence” and “slow decline non-adherence” groups that were presented by our model.39,47 This 
divergent finding may be due to many factors related to differences in disease characteristics, 
study population, or study design. 
In this study, we identified main characteristics and factors associated with the trajectory 
groups. The factors that were found to be significantly associated with poor or intermediate 
adherence patterns were race, CCI, CHADS2-VASc score, LIS, and being in Medicare coverage 
gap. Compared to white patients, Hispanic, Asian, and North American Native patients were 
more likely to have a moderate decline in their warfarin adherence in the first year of therapy, 
which is consistent with other studies.41,44 Also, our study reveals that patients in the “moderate” 
and “rapid decline non-adherence” groups had significantly higher comorbidities than patients in 
the “perfect adherence” group. Several studies have also concluded that comorbidity is 
associated highly with poor adherence.2,48  
The characteristics identified in this study may guide healthcare providers and clinicians to 
target patients who are more likely to have poor adherence to warfarin in the year following 
		 97	
initiation. For example, for patients who are at higher risk of discontinuing warfarin, such as 
Hispanic, Asian, and North American Native, the clinicians may need to educate them more 
about the importance of adherence and facilitate their access to healthcare resources and system. 
Moreover, by knowing characteristics of patients in each adherence trajectory we can 
identify the best timing to deliver an intervention. For example, if the patient is likely to be in the 
rapid decline group, as are patients with higher comorbidity, then clinicians may need to educate 
those patients at the beginning of the warfarin treatment and try to identify potential barriers of 
non-adherence such as cost, access to the healthcare system, or difficulty in managing disease 
conditions. 
Furthermore, some of these predictive factors are considered modifiable and can be used to 
tailor appropriate interventions in order to improve patient adherence. For instance, in our study, 
we found that patients who were not eligible for the LIS program were significantly more likely 
to be in the rapidly and moderately declining groups compared to the perfect adherence group. 
The LIS variable was used in this study as a proxy for patient income; however, LIS does not 
reflect the exact socioeconomic status of the beneficiary. A Medicare beneficiary may not be 
eligible for the LIS program but may still have a low income (i.e., income that does not reach the 
Medicare threshold for LIS eligibility). This finding suggests that, although a patient’s income 
may not be a modifiable factor, access to the healthcare system can be modifiable. Healthcare 
providers or payers may need to improve regulation to facilitate access to the healthcare system 
for the elderly population in order to enhance their medication adherence behavior and overall 
health outcomes. 
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5.2 Specific aim 2 and 3 
In the current study, the effect of warfarin adherence trajectories on AF-related 
hospitalization was assessed. We found that the risk of hospitalization was higher for the 
beneficiaries in lower adherence groups compared to beneficiaries in the perfect adherence 
trajectory. Patients with declining adherence and constantly moderate adherence had higher odds 
of being hospitalized in the year following warfarin initiation compared to patients who were 
well adherent to warfarin therapy. 
In previous studies, adherence trajectories have been shown to have a significant 
association with clinical outcomes for patients treated with statins, oral hypoglycemic 
medications, anti-epileptics, endocrine therapy, and antipsychotics. In contrast, in our study we 
did not observe any significant association between warfarin trajectory groups and AF-related 
hospitalization.38,44,45,47-49 A number of reasons can explain this finding. First, this lack of an 
association may be due to the lower number of hospitalization events captured in our data 
compared to previous studies. Lo-Ciganic et. al. reported that  the percentage of diabetes-related 
hospitalizations/ED visits among the trajectory groups ranged between 14% to 19.5%, a range 
sufficient to permit detection  of significant differences between the trajectory groups.47 
Conversely, the percentage of hospitalization events in our adherence groups ranges between 6-
9%. Hence, due to the small proportion of beneficiaries that had experienced hospitalization 
among the groups, we were not able to detect any significant differences. However, in the 
sensitivity analyses we redefined hospitalization by using all the diagnosis variables, and the 
number of hospitalization events increased, but we were still unable to observe a significant 
difference in the hospitalization risk among trajectory groups. Second, the clinical outcome 
measures in previous studies differ from those used in the current study. In our study we only 
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looked at the risk of AF-related hospitalization. However, in other studies, the clinical outcomes 
included ED visits with hospitalization events, and death. A study by MacEwan et. al, measured 
the impact of trajectory group membership on psychiatrics ED visits separately from psychiatrics 
hospitalization events and found significant differences in ED visits between trajectory groups. 
However, the authors did not report any significant association with hospitalization events 
between the trajectory groups.48  The third reason can be related to statistical issues. Each 
parameter estimate has a standard error, which measures the variation of the sample parameter 
from the population value. In the current study, the standard errors of the parameter estimates for 
the hazard ratio, especially for the smaller size trajectory groups (group 3 and 4) were very large 
and caused the confidence intervals to be wide. Hence, the hazard ratios for hospitalization were 
not statistically significant. In other words, when we classified 3,246 beneficiaries into six 
trajectory groups and used Cox proportional hazards modelling to compare the risk of 
hospitalization among the groups, the variation associated with the parameter estimates of the 
trajectory groups was found to be very high.   
Although we did not observe a significant association between warfarin adherence 
trajectories and AF-related hospitalization, we were still able to recognize the trend of 
hospitalization risk between the trajectory groups. Based on the results, we can see that the 
trajectory groups with declining adherence had a higher risk of being hospitalized in the year 
following warfarin initiating compared to adherent groups, which is consistent with other 
studies.44,45,47 
Moreover, in this study we were able to quantify AF-related cost associated with each 
trajectory group. To our knowledge, no previous study has assessed the economic impact of 
adherence trajectory groups and compared between them. We found that there were significant 
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differences between the monitoring costs and the outpatient costs among the adherence 
trajectories. The beneficiaries in the “perfect adherence trajectory” had the highest INR 
monitoring cost, which reflect the high number of anticoagulant clinic visits. Conversely, the 
beneficiaries in the “rapidly decline” and “moderate decline” trajectories had the lowest INR 
monitoring cost, and lowest number of anticoagulant clinic visits. This finding emphasizes the 
important role of anticoagulant clinic access in improving patients’ adherence to warfarin. This 
also is consistent with prior research.75 
Although were not able to detect significant differences in the inpatient costs and the 
overall direct medical costs among the trajectory groups, we were able to evaluate the trend in 
the AF-related cost among different trajectory groups. Accordingly, we found that average 
overall AF-related costs were higher for the beneficiaries with constantly moderate adherence or 
rapidly declining adherence in their first year of warfarin treatment compared to beneficiaries in 
the perfect adherence group. 
These findings provide insight for healthcare providers and payers on trajectory groups 
that are associated with higher cost and hence require more attention to improve their adherence 
and promote lower overall healthcare costs. 
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5.3 Strengths and limitations 
To the best of our knowledge, this is the first study that has used GBTM to identify 
adherence patterns for warfarin patients. The strength of our study is the use of the GBTM 
approach in identifying the distinct adherence trajectories of warfarin in elderly AF patients. 
Unlike traditional adherence measures, the GBTM accounts for the dynamic nature of the 
adherence behavior over time, and can thus distinguish between different adherence patterns. In 
the current study, we were able to identify six adherence trajectories for warfarin, which the PDC 
and other traditional adherence measures cannot distinguish. For example, with the application of 
a dichotomous PDC measure, patients in the “rapid decline non-adherence”, “moderate non-
adherence” and “moderate decline non-adherence” groups will all be classified as non-adherent 
although each group has a clearly different trajectory over time. Furthermore, we were able to 
identify the predictive factors associated with each adherence trajectory. This can guide 
clinicians and healthcare providers in identifying patients that are more likely to have poor 
adherence to warfarin and target them with appropriate interventions. For example, a patient who 
has a sustained moderate adherence over a long period of time, similar to patients in the 
“moderate non-adherence” group, would benefit from a different intervention than a patient who 
has decline in his adherence over time, such as patients in “moderate decline non-adherence” 
group. 
Moreover, in our study we used Medicare data, which is nationally representative and is a 
good source of health information, especially for the elderly population. Further, recall bias was 
reduced in our study as administrative data were used for warfarin refill information instead of 
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self-reported surveys. 
On the other hand, the study has several limitations. First, the selection of study 
population depends on the accuracy of the reported ICD-9 codes in the Medicare dataset, which 
may be subject to miscoding and misclassification, and hence could lead to inaccurate, though 
conservative, results. We tried to address this limitation by requiring AF patients to have at least 
one inpatient claim or two outpatient claims for AF in any of the 25 diagnosis variables in the 
Medicare files. Second, we measured patients’ monthly adherence based on the refill data, a 
method that may not capture actual consumption of warfarin. However, several studies have 
shown a high correlation between refill data and patient consumption.76,77 Third, due to 
limitations related to the data source, we were not able to examine the impact of some important 
predictive factors, such as: social support, marital status, educational level, patients’ belief, and 
medication-related adverse events. Also, Medicare data do not report the INR values and length 
of time within the therapeutic range (TTR), which are important factors when assessing the 
impact of warfarin therapy. The TTR reflect the quality of warfarin treatment, and hence can 
drive adherence behavior. The TTR can play big role in explain warfarin adherence trajectories 
and help in exploring reasons behind such trajectories. Moreover, we did not have information 
regarding beneficiary income level, which could have influenced adherence trajectories. 
However, we adjusted for this limitation, by using LIS eligibility as a proxy for low income, as 
recommended by other investigators.44 Fourth, we were not able to capture prescriptions 
dispensed outside of Medicare data (e.g., samples from physicians or medications purchased out 
of pocket), especially as warfarin is available as a $4 generic and can be affordable. Fifth, as 
warfarin is considered a critical drug (i.e., requiring regular dosage adjustment based on the INR 
level, correlated with many drug/food interaction, and associated with higher risk of 
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bleeding/stroke), the patient is likely to discontinue the treatment due to adverse events. For 
example, if the patient’s adherence level was initially good and then dropped, this could be 
related to unmeasured adverse events associated with warfarin use. However, in our study, we 
were unable to distinguish between treatment discontinuation and non-adherence. Sixth, due to 
the limited funding available for this study, we were only able to capture institutional resource 
utilization and associated costs. That is, we were not able to include the carrier file claims (non-
institutional- physician office-based outpatient claims). Therefore, the resources utilized, 
including access to anticoagulant clinics and associated costs were only reflective of the 
institutional perspective (i.e., hospital outpatient claims).  
Furthermore, some of the limitations of this study were related to the study’s design. For 
example, it is likely that non-adherence behavior had an impact shortly after it occurred. 
However, due to the time interval between the adherence measuring period and the outcome 
period (one year follow up period) in the current study, we cannot affirm that AF-related 
hospitalization is caused by adherence trajectories.  However, we tried to address this limitation 
in the sensitivity analysis, by testing a temporally closer three-months follow-up period, and the 
results were essentially unchanged from the main analysis. Moreover, we did not account for the 
hospitalization days when measuring monthly PDC. The hospitalization events occurring in the 
identification period may have an impact on adherence behaviors, and hence can paly role in 
describing adherence trajectories. 
An important point to consider with the GBTM, is that there might be more than the six 
identified warfarin adherence trajectories in the “real world”. However, as in the case with any 
statistical approach, the goal of the GBTM is provide simplification of the real-world situation in 
order to better understand the different adherence trajectories. 
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Finally, our study was restricted to the elderly Medicare population having no HMO 
coverage, so the results cannot be generalized to all AF patients treated with warfarin. Further 
research is needed to identify adherence trajectories in a wider, more generalizable population 
treated with warfarin. 
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5.4 Conclusion and future directions 
GBTM is a novel methodological approach that can be used to identify different patterns 
of warfarin adherence in elderly AF patients. In our study, we were able to identify six distinct 
adherence trajectories for new warfarin users that traditional adherence measures would not have 
been able to detect. The application of the GBTM enabled us to visualize and better understand 
changes in adherence behavior over time.  
In this study, we also identified several significant predictors associated with each 
trajectory group. These identified characteristics can enable healthcare providers to detect 
patients who are more likely to become non-adherent to warfarin soon after treatment initiation 
and determine the time when non-adherence may occur. Moreover, we evaluated the impact of 
each adherence trajectory on subsequent AF-hospitalization and calculated associated costs for 
each trajectory group. Hence, the findings of our study can help healthcare providers and payers 
to target those groups of patients who might be associated with higher resource utilization and 
healthcare costs. 
The usefulness of applying GBTM in clinical practice is defined by its ability to identify 
patients who are more likely to be in the poor or intermediate adherence groups, allowing 
providers and health systems to target them with the suitable adherence interventions. Our 
findings suggest that patients in the poor adherence groups may express different patterns of 
adherence over time. This may indicate, hence, that such patients could benefit from different 
interventions at different time points. Additionally, GBTM allows us to determine the timing of 
onset of non-adherence, helping to identify the optimal times to deliver an intervention and 
prevent further decline in adherence. For example, for patients who are likely to have rapid 
decline in their adherence, it is better to target them with a suitable intervention at the beginning 
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of treatment; while patients who might have slow decline in their adherence can be targeted with 
a reminder intervention at later time (e.g., after six months). Overall, early identification of 
patients at higher risk of non–adherence, and customization of suitable interventions for each 
trajectory group of patients can help to better allocate resources and ultimately to improve patient 
adherence and outcomes. 
Further research is needed to evaluate the most effective adherence intervention for each 
trajectory group. Moreover, there is increasing interest in the pharmacogenetics of warfarin 
therapy in clinical practice. The metabolism of warfarin and its therapeutic effectiveness are 
influenced by genetic variations. Pharmacogenetics can guide in estimating the appropriate dose 
of warfarin. Hence, future research should examine the impact of pharmacogenetics effects on 
warfarin adherence trajectories. Future research should also examine patterns of warfarin 
adherence for longer periods of time (e.g., a five year follow up measuring period). Given that 
warfarin is considered a life-long treatment for most AF patients, it would be of interest to 
examine the long-term adherence patterns of warfarin patients. Moreover, further research is 
needed to identify adherence patterns for warfarin in different populations and to compare 
between these. 
In conclusion, the results of this study illuminate important changes in adherence 
behavior for the new warfarin users. GBTM is considered a promising methodological approach 
that can be applied to the study of longitudinal adherence data and account for the dynamic 
nature of adherence behavior in a better way than traditional adherence measures.  
 
  
		 107	
 
 
 
 
 
 
 
 
List of References 
		 108	
List of References 
 
 
 
1. World Health Organization. Adherence to long-term therapies: Evidence for action. 2003. 
2. Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a 
conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with 
atrial fibrillation. J Manag Care Pharm. 2012;18(5):351-362. doi: 2012(18)5: 351-362 [pii]. 
3. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and 
outcome of ischemic stroke: Results from a population-based study. Stroke. 2005;36(6):1115-
1119. doi: 01.STR.0000166053.83476.4a [pii]. 
4. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: A 
report from the american heart association. Circulation. 2014;129(3):e28-e292. doi: 
10.1161/01.cir.0000441139.02102.80 [doi]. 
5. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management 
of patients with atrial fibrillation: A report of the american college of cardiology/american heart 
association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 
2014;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022 [doi]. 
6. Sanoski CA. Current approaches to anticoagulation for reducing risk of atrial fibrillation-
related stroke. J Pharm Pract. 2013;26(3):204-213. doi: 10.1177/0897190012452309 [doi]. 
7. http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm#healthcare. Updated 2014. Accessed 
jan\22, 2015. 
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in 
patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi: 
146/12/857 [pii]. 
		 109	
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial 
fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi: 10.1056/NEJMoa0905561 [doi]. 
10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial 
fibrillation. N Engl J Med. 2011;365(10):883-891. doi: 10.1056/NEJMoa1009638 [doi]. 
11. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients 
undergoing cardioversion of atrial fibrillation (ENSURE-AF): A randomised, open-label, phase 
3b trial. Lancet. 2016;388(10055):1995-2003. doi: S0140-6736(16)31474-X [pii]. 
12. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with 
warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary 
analysis of a randomised controlled trial. Lancet. 2012;380(9855):1749-1758. doi: 
10.1016/S0140-6736(12)60986-6 [doi]. 
13. Hanley CM, Kowey PR. Are the novel anticoagulants better than warfarin for patients with 
atrial fibrillation? J Thorac Dis. 2015;7(2):165-171. doi: 10.3978/j.issn.2072-1439.2015.01.23 
[doi]. 
14. Huang C, Siu M, Vu L, Wong S, Shin J. Factors influencing doctors' selection of dabigatran 
in non-valvular atrial fibrillation. J Eval Clin Pract. 2013;19(5):938-943. doi: 10.1111/j.1365-
2753.2012.01886.x [doi]. 
15. Nutescu EA. Anticoagulation management services: Entering a new era. Pharmacotherapy. 
2010;30(4):327-329. doi: 10.1592/phco.30.4.327 [doi]. 
16. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events 
among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116. doi: joc21714 
[pii]. 
		 110	
17. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for 
adverse drug events in older americans. N Engl J Med. 2011;365(21):2002-2012. doi: 
10.1056/NEJMsa1103053 [doi]. 
18. Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation 
control with warfarin: Results from the international normalized ratio adherence and genetics 
(IN-RANGE) study. Arch Intern Med. 2007;167(3):229-235. doi: 167/3/229 [pii]. 
19. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality 
of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632-636. doi: aph.1E464 [pii]. 
20. Socha T. UNDERUTILIZATION OF WARFARIN AND ASSOCIATED COSTS. 2012. 
21. Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: A new approach to 
classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789-796. doi: 
10.1097/MLR.0b013e3182984c1f [doi]. 
22. Franklin JM, Krumme AA, Tong AY, et al. Association between trajectories of statin 
adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 
2015;24(10):1105-1113. doi: 10.1002/pds.3787 [doi]. 
23. Lo-Ciganic WH, Donohue JM, Jones BL, et al. Trajectories of diabetes medication adherence 
and hospitalization risk: A retrospective cohort study in a large state medicaid program. J Gen 
Intern Med. 2016;31(9):1052-1060. doi: 10.1007/s11606-016-3747-6 [doi]. 
24. Nagin DS. Group-based trajectory modeling: An overview. Ann Nutr Metab. 2014;65(2-
3):205-210. doi: 10.1159/000360229 [doi]. 
25. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin 
Psychol. 2010;6:109-138. doi: 10.1146/annurev.clinpsy.121208.131413 [doi]. 
		 111	
26. Muthen B, Muthen LK. Integrating person-centered and variable-centered analyses: Growth 
mixture modeling with latent trajectory classes. Alcohol Clin Exp Res. 2000;24(6):882-891. 
27. Librero J, Sanfelix-Gimeno G, Peiro S. Medication adherence patterns after hospitalization 
for coronary heart disease. A population-based study using electronic records and group-based 
trajectory models. PLoS One. 2016;11(8):e0161381. doi: 10.1371/journal.pone.0161381 [doi]. 
28. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the 
management of patients with atrial fibrillation-executive summary: A report of the american 
college of cardiology/american heart association task force on practice guidelines and the 
european society of cardiology committee for practice guidelines (writing committee to revise 
the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J. 
2006;27(16):1979-2030. doi: 27/16/1979 [pii]. 
29. Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in 
patients with atrial fibrillation- quality and cost implications. Am J Med. 2014;127(11):1075-
82.e1. doi: 10.1016/j.amjmed.2014.05.013 [doi]. 
30.     National action plan for adverse drug prevention: Anticoagulants. 
https://health.gov/hcq/pdfs/ADE-Action-Plan-Anticoagulants.pdf. Updated 2016. Accessed 
Nov/15, 2016. 
31. Obamiro KO, Chalmers L, Bereznicki LR. A summary of the literature evaluating adherence 
and persistence with oral anticoagulants in atrial fibrillation. Am J Cardiovasc Drugs. 
2016;16(5):349-363. doi: 10.1007/s40256-016-0171-6 [doi]. 
32. Aarnio E, Martikainen J, Winn AN, Huupponen R, Vahtera J, Korhonen MJ. Socioeconomic 
inequalities in statin adherence under universal coverage: Does sex matter? Circ Cardiovasc 
Qual Outcomes. 2016. doi: CIRCOUTCOMES.116.002728 [pii]. 
		 112	
33. Librero J, Sanfelix-Gimeno G, Peiro S. Medication adherence patterns after hospitalization 
for coronary heart disease. A population-based study using electronic records and group-based 
trajectory models. PLoS One. 2016;11(8):e0161381. doi: 10.1371/journal.pone.0161381 [doi]. 
34. Mardby AC, Schioler L, Sundell KA, Bjerkeli P, Lesen E, Jonsson AK. Adherence to 
antidepressants among women and men described with trajectory models: A swedish 
longitudinal study. Eur J Clin Pharmacol. 2016;72(11):1381-1389. doi: 10.1007/s00228-016-
2106-1 [doi]. 
35. Chen CC, Cheng SH. Continuity of care and changes in medication adherence among 
patients with newly diagnosed diabetes. Am J Manag Care. 2016;22(2):136-142. doi: 86530 
[pii]. 
36. Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of 
changes in self-reported adherence to antiretroviral therapy: Swiss HIV cohort study. J Acquir 
Immune Defic Syndr. 2010;54(2):197-203. doi: 10.1097/QAI.0b013e3181ca48bf [doi]. 
37. Dillon P, Stewart D, Smith SM, Gallagher P, Cousins G. Group-based trajectory models: 
Assessing adherence to antihypertensive medication in older adults in a community pharmacy 
setting. Clin Pharmacol Ther. 2017. doi: 10.1002/cpt.865 [doi]. 
38. Modi AC, Wu YP, Rausch JR, Peugh JL, Glauser TA. Antiepileptic drug nonadherence 
predicts pediatric epilepsy seizure outcomes. Neurology. 2014;83(22):2085-2090. doi: 
10.1212/WNL.0000000000001023 [doi]. 
39. Modi AC, Rausch JR, Glauser TA. Patterns of nonadherence to antiepileptic drug therapy in 
children with newly diagnosed epilepsy. JAMA. 2011;305(16):1669-1676. doi: 
10.1001/jama.2011.506 [doi]. 
		 113	
40. Greenley RN, Karazsia B, Schurman JV, et al. Trajectories of oral medication adherence in 
youth with inflammatory bowel disease. Health Psychol. 2015;34(5):514-521. doi: 
10.1037/hea0000149 [doi]. 
41. Franklin JM, Krumme AA, Shrank WH, Matlin OS, Brennan TA, Choudhry NK. Predicting 
adherence trajectory using initial patterns of medication filling. Am J Manag Care. 
2015;21(9):e537-44. doi: 86318 [pii]. 
42. Juarez DT, Williams AE, Chen C, et al. Factors affecting medication adherence trajectories 
for patients with heart failure. Am J Manag Care. 2015;21(3):e197-205. doi: 86047 [pii]. 
43. Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: A new approach to 
classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789-796. doi: 
10.1097/MLR.0b013e3182984c1f [doi]. 
44. Hargrove JL, Pate V, Casteel CH, et al. Antihypertensive adherence trajectories among older 
adults in the first year after initiation of therapy. Am J Hypertens. 2017;30(10):1015-1023. doi: 
10.1093/ajh/hpx086 [doi]. 
45. Franklin JM, Krumme AA, Tong AY, et al. Association between trajectories of statin 
adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 
2015;24(10):1105-1113. doi: 10.1002/pds.3787 [doi]. 
46. Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: A new approach to 
classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789-796. doi: 
10.1097/MLR.0b013e3182984c1f [doi]. 
47. Lo-Ciganic WH, Donohue JM, Jones BL, et al. Trajectories of diabetes medication adherence 
and hospitalization risk: A retrospective cohort study in a large state medicaid program. J Gen 
Intern Med. 2016;31(9):1052-1060. doi: 10.1007/s11606-016-3747-6 [doi]. 
		 114	
48. MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP. Patterns of 
adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag 
Care Spec Pharm. 2016;22(11):1349-1361. doi: 10.18553/jmcp.2016.22.11.1349 [doi]. 
49. Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of 
glaucoma medication adherence over four years of follow-up. Ophthalmology. 
2015;122(10):2010-2021. doi: 10.1016/j.ophtha.2015.06.039 [doi]. 
50. Li Y, Zhou H, Cai B, et al. Group-based trajectory modeling to assess adherence to biologics 
among patients with psoriasis. Clinicoecon Outcomes Res. 2014;6:197-208. doi: 
10.2147/CEOR.S59339 [doi]. 
51. Murray MD, Morrow DG, Weiner M, et al. A conceptual framework to study medication 
adherence in older adults. Am J Geriatr Pharmacother. 2004;2(1):36-43. doi: 
S1543594604900050 [pii]. 
52. Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of 
adherence to medications and behavioral treatment and their relationship to patient 
characteristics and treatment response. Addict Behav. 2013;38(5):2119-2127. doi: 
10.1016/j.addbeh.2013.01.024 [doi]. 
53. Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy 
adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 
2016;25(8):953-959. doi: 10.1002/pds.4012 [doi]. 
54. Nagin DS. Group-based trajectory modeling: An overview. Ann Nutr Metab. 2014;65(2-
3):205-210. doi: 10.1159/000360229 [doi]. 
55. Josh Unni E. Development of models to predict medication non-adherence based on a new 
typology  [Phd]. University of Iowa; 2008. 
		 115	
56. Carolyn B. ResearcConceptualizing researchh method for pharmaceutical practice and 
policy. In: Aparasu R, ed. Research method for pharmaceutical practice and policy. 
Pharmaceutical Press; 2011:17-36. 
57. Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a 
conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with 
atrial fibrillation. J Manag Care Pharm. 2012;18(5):351-362. doi: 2012(18)5: 351-362 [pii]. 
58. Chronic condition data WarehouseEstimate study size. 
https://www.ccwdata.org/web/guest/pricing/estimate-study-size. Updated 2018. Accessed 
Jan/25, 2018. 
59. Chronic Conditions Data Warehouse. CCW technical guidance: Options for determining 
which CMS medicare beneficiaries are dually eligible for medicare and medicaid benefits  . . 
2015. 
60. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 
1987;40(5):373-383. 
61. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-
CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619. doi: 0895-4356(92)90133-
8 [pii]. 
62. DiMatteo MR. Variations in patients' adherence to medical recommendations: A quantitative 
review of 50 years of research. Med Care. 2004;42(3):200-209. doi: 00005650-200403000-
00002 [pii]. 
63. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. 
doi: 353/5/487 [pii]. 
		 116	
64. Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of compliance 
with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc. 
2009;101(1):34-39. doi: S0027-9684(15)30808-7 [pii]. 
65. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic 
medication in a population of patients with type 2 diabetes: A retrospective cohort study. Diabet 
Med. 2002;19(4):279-284. doi: 689 [pii]. 
66. Zhang Y, Lave JR, Donohue JM, Fischer MA, Chernew ME, Newhouse JP. The impact of 
medicare part D on medication adherence among older adults enrolled in medicare-advantage 
products. Med Care. 2010;48(5):409-417. doi: 10.1097/MLR.0b013e3181d68978 [doi]. 
67. Zhao B ea. Estimating patient adherence to medication with electronic health records data 
and pharmacy claims combined. 2013;167-2013. 
68. https://www.andrew.cmu.edu/user/bjones/. Updated 2017. Accessed 03/29, 2018. 
69. Librero J, Sanfelix-Gimeno G, Peiro S. Medication adherence patterns after hospitalization 
for coronary heart disease. A population-based study using electronic records and group-based 
trajectory models. PLoS One. 2016;11(8):e0161381. doi: 10.1371/journal.pone.0161381 [doi]. 
70. Arrandale V ea. How to use SAS® proc traj and SAS® proc glimmix in Respiratory 
epidemiology. 2006. 
71. Andruff H ea. Latent class growth modelling: A tutorial Tutorials in Quantitative Methods 
for Psychology. 2009;Vol. 5(1):11-24. 
72. https://ycharts.com/indicators/us_health_care_inflation_rate. Updated 2018. Accessed 05/20, 
2018. 
73. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for 
hypertension in actual practice. CMAJ. 1999;160(1):31-37. 
		 117	
74. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A 
review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-286. 
75. Chamberlain MA, Sageser NA, Ruiz D. Comparison of anticoagulation clinic patient 
outcomes with outcomes from traditional care in a family medicine clinic. J Am Board Fam 
Pract. 2001;14(1):16-21. 
76. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims 
database to estimate medication adherence in older persons. Med Care. 2006;44(5):471-477. doi: 
10.1097/01.mlr.0000207817.32496.cb [doi]. 
77. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: 
Methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116. doi: 
S0895435696002685 [pii]. 
  
 
 
 
  
		 118	
Appendix A 
 
 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure A.1: Conceptual framework based on Andersen Behavioral model (ABM) 
Predisposing factors Enabling factors Need factors 
Demographic: 
• Age 
• Gender 
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Personal: 
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Appendix B 
 
Table B.1: Percent change in Consumer price index (CPI) from 2009-2018 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Medical care 
services 
3.62% 2.87% 3.43% 2.75% 2.42% 2.90% 2.98% 2.95% 2.21% 
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Appendix C 
 
	
 
 
Figure C.1: Log minus log curve of the six trajectory groups and time to first hospitalization 
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Appendix D 
 
 
 
 
Figure D.1:  Smoothed hazard ratio estimates using Schoenfeld residuals (Schres) 
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Appendix E 
 
Table E.1:  Smoothed hazard ratio estimates using Schoenfeld residuals 
 
Variable  Parameter 
estimate 
Standard error P-value 
Intercept  -0.02 0.04 0.63 
Time to first hospitalization 0.0001 0.0002 0.57 
 
 
 
 
 
 
 
 
 
 
 
 
